U.S. patent application number 11/226852 was filed with the patent office on 2006-02-16 for dark quenchers for donor-acceptor energy transfer.
This patent application is currently assigned to Biosearch Technologies, Inc.. Invention is credited to Ronald M. Cook, Daren Dick, Matt Lyttle.
Application Number | 20060035262 11/226852 |
Document ID | / |
Family ID | 24268941 |
Filed Date | 2006-02-16 |
United States Patent
Application |
20060035262 |
Kind Code |
A1 |
Cook; Ronald M. ; et
al. |
February 16, 2006 |
Dark quenchers for donor-acceptor energy transfer
Abstract
The present invention provides a family of dark quenchers,
termed Black Hole Quenchers ("BHQs"), that are efficient quenchers
of excited state energy but which are themselves substantially
non-fluorescent. Also provided are methods of using the BHQs,
probes incorporating the BHQs and methods of using the probes.
Inventors: |
Cook; Ronald M.; (Novato,
CA) ; Lyttle; Matt; (Point Reyes Station, CA)
; Dick; Daren; (San Geronimo, CA) |
Correspondence
Address: |
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P O BOX 458
ALAMEDA
CA
94501
US
|
Assignee: |
Biosearch Technologies,
Inc.
Novato
CA
|
Family ID: |
24268941 |
Appl. No.: |
11/226852 |
Filed: |
September 13, 2005 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11192705 |
Jul 29, 2005 |
|
|
|
11226852 |
Sep 13, 2005 |
|
|
|
09567863 |
May 9, 2000 |
|
|
|
11192705 |
Jul 29, 2005 |
|
|
|
Current U.S.
Class: |
435/6.12 ;
534/727; 536/24.3; 536/25.32 |
Current CPC
Class: |
C09B 31/043 20130101;
C07D 241/46 20130101; C07F 9/2408 20130101; C09B 56/00 20130101;
C07H 21/00 20130101; C09B 56/12 20130101; C07B 2200/11 20130101;
C07F 9/091 20130101; C07C 245/08 20130101; G01N 33/542 20130101;
C40B 40/00 20130101; G01N 33/582 20130101; C12Q 1/6818
20130101 |
Class at
Publication: |
435/006 ;
536/025.32; 534/727; 536/024.3 |
International
Class: |
C12Q 1/68 20060101
C12Q001/68; C07H 21/04 20060101 C07H021/04 |
Claims
1-87. (canceled)
88. A compound having the formula: ##STR15## wherein Ar.sup.1 and
Ar.sup.2 are each independently a substituted or unsubstituted aryl
group, where at least one of Ar.sup.1 and Ar.sup.2 is a substituted
aryl; X.sub.1 is selected from the group consisting of OH,
O-dimethoxytrityl, O-methoxytrityl, O-trityl and an oxygen atom
having an acid labile blocking group; X.sub.2 is a phosphoramidite;
and W is a linking group having from 3 to 100 backbone atoms
selected from C, N, O, S, Si and P, said linking group being
cyclic, acyclic, aromatic or a combination thereof.
89. A compound having the formula: ##STR16## wherein Ar.sup.1 and
Ar.sup.2 are each independently a substituted or unsubstituted aryl
group, where at least one of Ar.sup.1 and Ar.sup.2 is a substituted
aryl; X.sub.1 is selected from the group consisting of H,
(C.sub.1-C.sub.1-C12)alkyl, aryl, heteroaryl, and protected or
unprotected functional group; X.sub.2 is selected from the group
consisting of a phosphorous coupling moiety, a pentafluorophenoxy
moiety and a succinimidyl moiety; and W is a linking group having
from 3 to 100 backbone atoms selected from C, N, O, S, Si and P,
said linking group being cyclic, acyclic, aromatic or a combination
thereof.
90. A compound having the formula: ##STR17## wherein Ar.sup.1 and
Ar.sup.2 are each independently a substituted or unsubstituted aryl
group, where at least one of Ar.sup.1 and Ar.sup.2 is a substituted
aryl; X.sub.1, is selected from the group consisting of H,
(C.sub.1-C.sub.12)alkyl, aryl, heteroaryl and protected or
unprotected functional group; X.sub.2 is a phosphoramidite; and W
is a linking group having from 3 to 100 backbone atoms selected
from C, N, O, S, Si and P, said linking group being cyclic,
acyclic, aromatic or a combination thereof.
91. A compound having the formula: ##STR18## wherein Ar.sup.1 and
Ar.sup.2 are each independently a substituted or unsubstituted aryl
group; X.sub.1 is selected from the group consisting of H,
(C.sub.1-C.sub.12)alkyl, aryl, heteroaryl, and protected or
unprotected finctional group; X.sub.2 is a moiety reactive towards
nucleophiles; W is a linking group having from 3 to 100 backbone
atoms selected from C, N, O, S, Si and P, said linking group being
cyclic, acyclic, aromatic or a combination thereof; and wherein one
of Ar.sup.1 and A.sup.2 is directly or indirectly substituted with
a substituted aryl group (A.sup.3), where Ar.sup.3 extends the
resonance ability of the Ar.sup.1--N.dbd.N-A.sup.2 aromatic system
and thereby increases the wavelength absorbance maximum of the
compound.
92. A compound of claim 91 wherein Ar.sup.1 is directly substituted
with Ar.sup.3.
93. A compound of claim 91 wherein Ar.sup.1 is indirectly
substituted with Ar.sup.3.
94. A compound of claim 91 wherein A.sup.2 is directly substituted
with Ar.sup.3.
95. A compound of claim 91 wherein Ar.sup.2 is indirectly
substituted with Ar.sup.3.
96. A compound having the formula: ##STR19## wherein Ar.sup.1 and
A.sup.2 are each independently a substituted or unsubstituted aryl
group; X.sub.1, is selected from the, group consisting of H,
(C.sub.1-C.sub.12)alkyl, aryl, heteroaryl, and protected or
unprotected functional group; X.sub.2 is a phosphoramidite; W is a
linking group having from 3 to 100 backbone atoms selected from C,
N, O, S, Si and P, said linking group being cyclic, acyclic,
aromatic or a combination thereof; and wherein Ar.sup.1 or Ar.sup.2
is indirectly substituted with an aryl group through a group
selected from --(C.dbd.C).sub.n-- and --(CR'CR').sub.n-- where n is
0 to 5 and R' is independently selected from hydrogen,
(C.sub.1-C.sub.8)alkyl and heteroalkyl, unsubstituted aryl and
heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and (u
nsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl.
97. A compound having the formula: ##STR20## wherein Ar.sup.1 and
Ar.sup.2 are each independently a substituted or unsubstituted aryl
group; X.sub.1 is selected from the group consisting of H,
(C.sub.1-C.sub.12)alkyl, aryl, heteroaryl, and protected or
unprotected functional group; X.sub.2 is a phosphoramidite; W is a
linking group having from 3 to 100 backbone atoms selected from C,
N, O, S, Si and P, said linking group being cyclic, acyclic,
aromatic or a combination thereof; and Ar.sup.1 or Ar.sup.2 is
indirectly substituted with an aryl group (Ar.sup.3) through a
double bond selected from carbon-carbon and nitrogen-nitrogen
double bonds.
98. A compound having the formula: ##STR21## wherein Ar.sup.1 and
A.sup.2 are each independently a substituted or unsubstituted aryl
group; X.sub.1 is selected from the group consisting of H,
(C.sub.1-C.sub.12)alkyl, aryl, heteroaryl, and protected or
unprotected functional group; X.sub.2 is a phosphoramidite; W is a
linking group having from 3 to 100 backbone atoms selected from C,
N, O, S, Si and P, said linking group being cyclic, acyclic,
aromatic or a combination thereof; wherein one of Ar.sup.1 and
Ar.sup.2 is directly or indirectly substituted with a substituted
aryl group (Ar.sup.3), where Ar.sup.3 extends the resonance ability
of the Ar.sup.1--N.dbd.N--Ar.sup.2 aromatic system and thereby
increases the wavelength absorbance maximum of the compound; and at
least one of Ar.sup.1, A.sup.2and Ar.sup.3is substituted with
-halogen, --OR', --OC(O)R', --NR'R'', --SR', --R', --CN,
--NO.sub.2, --CO.sub.2R', --CONR'R'', --C(O)R', --OC(O)NR'R'',
--NR''C(O)R', --NRC''C(O).sub.2R', --NR'--C(O)NR''R''',
--NH--C(NH.sub.2)NH, --NR'C(NH.sub.2)NH, --NH--C(NH.sub.2).dbd.NR',
--S(O)R', --S(O).sub.2R', --S(O).sub.2NR'R'', --N3, --CH(Ph).sub.2,
perfluoro(C.sub.1-C.sub.4)alkoxy, and
perfluoro(C.sub.1-C.sub.4)alkyl, in a number ranging from zero to
the total number of open valences on the aromatic ring system; and
where R', R'' and R''' are independently selected from hydrogen,
(C.sub.1-C.sub.8)alkyl and heteroalkyl, unsubstituted aryl and
heteroaryl, (unsubstituted aryl)-(C.sub.1-C.sub.4)alkyl, and
(unsubstituted aryl)oxy-(C.sub.1-C.sub.4)alkyl.
99. A compound of claim 88 wherein W is acylic.
100. A compound of claim 88 wherein W comprises a cyclic group.
101. A compound of claim 89 wherein W is a cyclic.
102. A compound of claim 89 wherein W comprises a cyclic group.
103. A compound of claim 90 wherein W is acyclic.
104. A compound of claim 90 wherein W comprises a cyclic group.
105. A compound of claim 91 wherein W is acyclic.
106. A compound of claim 91 wherein W comprises a cyclic group.
107. A compound of claim 92 wherein W is acyclic.
108. A compound of claim 92 wherein W comprises a cyclic group.
109. A compound of claim 93 wherein W is a cyclic.
110. A compound of claim 93 wherein W comprises a cyclic group.
111. A compound of claim 94 wherein W is acyclic.
112. A compound of claim 94 wherein W comprises a cyclic group.
113. A compound of claim 95 wherein W is acyclic.
114. A compound of claim 95 wherein W comprises a cyclic group.
115. A compound of claim 96 wherein W is acyclic.
116. A compound of claim 96 wherein W comprises a cyclic group.
117. A compound of claim 97 wherein W is cyclic.
118. A compound of claim 97 wherein W comprises a cyclic group.
119. A compound of claim 98 wherein W is acyclic.
120. A compound of claim 98 wherein W comprises a cyclic group.
121. A compound of claims 89, 91-95 or 105-114 wherein X.sub.2 is a
phosphoramidite.
Description
BACKGROUND OF THE INVENTION
[0001] There is a continuous and expanding need for rapid, highly
specific methods of detecting and quantifying chemical, biochemical
and biological substances as analytes in research and diagnostic
mixtures. Of particular value are methods for measuring small
quantities of nucleic acids, peptides, pharmaceuticals,
metabolites, microorganisms and other materials of diagnostic
value. Examples of such materials include narcotics and poisons,
drugs administered for therapeutic purposes, hormones, pathogenic
microorganisms and viruses, antibodies, and enzymes and nucleic
acids, particularly those implicated in disease states.
[0002] The presence of a particular analyte can often be determined
by binding methods that exploit the high degree of specificity,
which characterizes many biochemical and biological systems.
Frequently used methods are based on, for example, antigen-antibody
systems, nucleic acid hybridization techniques, and protein-ligand
systems. In these methods, the existence of a complex of diagnostic
value is typically indicated by the presence or absence of an
observable "label" which has been attached to one or more of the
interacting materials. The specific labeling method chosen often
dictates the usefulness and versatility of a particular system for
detecting an analyte of interest. Preferred labels are inexpensive,
safe, and capable of being attached efficiently to a wide variety
of chemical, biochemical, and biological materials without
significantly altering the important binding characteristics of
those materials. The label should give a highly characteristic
signal, and should be rarely, and preferably never, found in
nature. The label should be stable and detectable in aqueous
systems over periods of time ranging up to months. Detection of the
label is preferably rapid, sensitive, and reproducible without the
need for expensive, specialized facilities or the need for special
precautions to protect personnel. Quantification of the label is
preferably relatively independent of variables such as temperature
and the composition of the mixture to be assayed.
[0003] A wide variety of labels have been developed, each with
particular advantages and disadvantages. For example, radioactive
labels are quite versatile, and can be detected at very low
concentrations, such labels are, however, expensive, hazardous, and
their use requires sophisticated equipment and trained personnel.
Thus, there is wide interest in non-radioactive labels,
particularly in labels that are observable by spectrophotometric,
spin resonance, and luminescence techniques, and reactive
materials, such as enzymes that produce such molecules.
[0004] Labels that are detectable using fluorescence spectroscopy
are of particular interest, because of the large number of such
labels that are known in the art. Moreover, the literature is
replete with syntheses of fluorescent labels that are derivatized
to allow their facile attachment to other molecules, and many such
fluorescent labels are commercially available.
[0005] In addition to being directly detected, many fluorescent
labels operate to quench the fluorescence of an adjacent second
fluorescent label. Because of its dependence on the distance and
the magnitude of the interaction between the quencher and the
fluorophore, the quenching of a fluorescent species provides a
sensitive probe of molecular conformation and binding, or other,
interactions. An excellent example of the use of fluorescent
reporter quencher pairs is found in the detection and analysis of
nucleic acids.
[0006] Fluorescent nucleic acid probes are important tools for
genetic analysis, in both genomic research and development, and in
clinical medicine. As information from the Human Genome Project
accumulates, the level of genetic interrogation mediated by
fluorescent probes will expand enormously. One particularly useful
class of fluorescent probes includes self-quenching probes, also
known as fluorescence energy transfer probes, or FET probes. The
design of different probes using this motif may vary in detail. In
an exemplary FET probe, both a fluorophore and a quencher are
tethered to nucleic acid. The probe is configured such that the
fluorophore is proximate to the quencher and the probe produces a
signal only as a result of its hybridization to an intended target.
Despite the limited availability of FET probes, techniques
incorporating their use are rapidly displacing alternative
methods.
[0007] Probes containing a fluorophore-quencher pair have been
developed for nucleic acid hybridization assays where the probe
forms a hairpin structure, i.e., where the probe hybridizes to
itself to form a loop such that the quencher molecule is brought
into proximity with the reporter molecule in the absence of a
complementary nucleic acid sequence to prevent the formation of the
hairpin structure (see, for example, WO 90/03446; European Patent
Application No. 0 601 889 A2). When a complementary target sequence
is present, hybridization of the probe to the complementary target
sequence disrupts the hairpin structure and causes the probe to
adopt a conformation where the quencher molecule is no longer close
enough to the reporter molecule to quench the reporter molecule. As
a result, the probes provide an increased fluorescence signal when
hybridized to a target sequence than when they are unhybridized
[0008] Assays have also been developed for detecting a selected
nucleic acid sequence and for identifying the presence of a hairpin
structure using two separate probes, one containing a reporter
molecule and the other a quencher molecule (see, Meringue, et al.,
Nucleic Acids Research, 22: 920-928 (1994)). In these assays, the
fluorescence signal of the reporter molecule decreases when
hybridized to the target sequence due to the quencher molecule
being brought into proximity with the reporter molecule.
[0009] One particularly important application for probes including
a reporter--quencher molecule pair is their use in nucleic acid
amplification reactions, such as polymerase chain reactions (PCR),
to detect the presence and amplification of a target nucleic acid
sequence. In general, nucleic acid amplification techniques have
opened broad new approaches to genetic testing and DNA analysis
(see, for example, Arnheim et al. Ann. Rev. Biochem., 61: 131-156
(1992)). PCR, in particular, has become a research tool of major
importance with applications in, for example, cloning, analysis of
genetic expression, DNA sequencing, genetic mapping and drug
discovery (see, Arnheim et al., supra; Gilliland et al., Proc.
Natl. Acad. Sci. USA, 87: 2725-2729 (1990); Bevan et al., PCR
Methods and Applications, 1: 222-228 (1992); Green et al., PCR
Methods and Applications, 1: 77-90 (1991); Blackwell et al.,
Science, 250: 1104-1110 (1990)).
[0010] Commonly used methods for detecting nucleic acid
amplification products require that the amplified product be
separated from unreacted primers. This is typically achieved either
through the use of gel electrophoresis, which separates the
amplification product from the primers on the basis of a size
differential, or through the immobilization of the product,
allowing free primer to be washed away. However, a number of
methods for monitoring the amplification process without prior
separation of primer have been described. All of them are based on
FET, and none of them detect the amplified product directly.
Instead, the methods detect some event related to amplification.
For that reason, they are accompanied by problems of high
background, and are not quantitative, as discussed below.
[0011] One method, described in Wang et al. (U.S. Pat. No.
5,348,853; and Anal. Chem., 67: 1197-1203 (1995)), uses an energy
transfer system in which energy transfer occurs between two
fluorophores on the probe. In this method, detection of the
amplified molecule takes place in the amplification reaction
vessel, without the need for a separation step. This method,
however, does not detect the amplified product, but instead detects
the dissociation of primer from the "energy-sink" nucleic acid.
Thus, this method is dependent on detection of a decrease in
emissions; a significant portion of labeled primer must be utilized
in order to achieve a reliable difference between the signals
before and after the reaction.
[0012] A second method detecting an amplification product without
prior separation of primer and product is the 5'-nuclease PCR assay
(also referred to as the TaqMan.TM. assay) (Holland et al., Proc.
Natl. Acad. Sci. USA, 88: 7276-7280 (1991); Lee et al., Nucleic
Acids Res., 21: 3761-3766 (1993)). This assay detects the
accumulation of a specific PCR product by hybridization and
cleavage of a doubly labeled fluorogenic probe (the "TaqMan" probe)
during the amplification reaction. The fluorogenic probe consists
of an nucleic acid labeled with both a fluorescent reporter dye and
a quencher dye. During PCR, this probe is cleaved by the
5'-exonuclease activity of DNA polymerase if, and only if, it
hybridizes to the segment being amplified. Cleavage of the probe
generates an increase in the fluorescence intensity of the reporter
dye.
[0013] In the TaqMan assay, the donor and quencher are preferably
located on the 3'- and 5'-ends of the probe, because the
requirement that 5'-3' hydrolysis be performed between the
fluorophore and quencher may be met only when these two moieties
are not too close to each other (Lyamichev et al., Science,
260:778-783 (1993)). This requirement is a serious drawback of the
assay as the efficiency of energy transfer decreases with the
inverse sixth power of the distance between the reporter and
quencher. Thus, if the quencher is not close enough to the reporter
to achieve the most efficient quenching the background emissions
from the probe can be quite high.
[0014] Yet another method of detecting amplification products that
relies on the use of energy transfer is the "beacon probe" method
described by Tyagi et al. (Nature Biotech., 14:303-309 (1996))
which is also the subject of U.S. Pat. No. 5,312,728 to Lizardi et
al. This method employs nucleic acid hybridization probes that can
form hairpin structures. On one end of the hybridization probe
(either the 5'- or 3'-end) there is a donor fluorophore, and on the
other end, an acceptor moiety. In this method, the acceptor moiety
is a quencher, absorbing energy from the donor. Thus when the
beacon is in the open conformation, the fluorescence of the donor
fluorophore is detectable, whereas when the beacon is in hairpin
(closed) conformation, the fluorescence of the donor fluorophore is
quenched. When employed in PCR, the molecular beacon probe, which
hybridizes to one of the strands of the PCR product, is in "open
conformation," and fluorescence is detected, while those that
remain unhybridized will not fluoresce. As a result, the amount of
fluorescence will increase as the amount of PCR product increases,
and thus can be used as a measure of the progress of the PCR.
[0015] Certain limitations impede the application and use of FET
probes, or result in assays that are less sensitive than they could
be. Foremost among these limitations is the presence of background
fluorescence attributable to the emission of the quencher, giving
the probe a higher fluorescent noise background than is desirable.
An approach that has been utilized to ameliorate this limitation is
the use of a quencher that is not a fluorophore ("dark quenchers"),
such as derivatives of 4-(dimethylamino)azobenzene (DABCYL). DABCYL
is useful as a quenching agent for a limited group of fluorophores
with whose emission characteristics, the absorption characteristics
of DABCYL overlap. The limited absorption range of DABCYL restricts
the utility of this compound by allowing the use of a limited
number of fluorophores in conjunction with DABCYL. Because
relatively few fluorophores can be used with DABCYL in FET pairs,
multiplex applications, where it is desired to use two or more
fluorophores with clearly resolved fluorescence emission spectra
are difficult to design using this quencher.
[0016] In view of the limitations of presently available dark
quenchers and probes, such as FET probes constructed with these
quenchers, there exists in the art a need for improved quenchers
that can be incorporated into probes for detecting analytes
rapidly, sensitively, reliably and quantitatively. Ideal quenchers
would be have little to no fluorescent quenching signal, and be
easily and inexpensively prepared. Moreover, a series of quenchers
having similar physical properties, but distinct spectral
properties would be particularly advantageous. Quite surprisingly,
the present invention provides such quenchers, probes incorporating
these quenchers and methods for using the quenchers and probes.
SUMMARY OF THE INVENTION
[0017] The present invention provides a family of quenchers of
excited state energy that are substantially non-fluorescent, termed
"Black Hole Quenchers" ("BHQs"). The quenchers of the invention
remedy many of the deficiencies of currently utilized dark
quenchers, probes assembled using these quenchers and methods using
such quenchers and probes. The present invention provides a class
of dark quenchers that are functionalized to allow their rapid
attachment to probe components using techniques well known in the
art, or modifications of such techniques that are well within the
abilities of those of skill in the art. Moreover, the present
invention provides a class of dark quenchers that can be engineered
to have a desired light absorption profile. The provision of this
class of dark quenchers represents a substantial improvement in the
design of probes incorporating dark quenchers and methods using
such probes.
[0018] Many of the nucleic acid probes presently used rely on an
interaction between the fluorophore and the quencher in order to
minimize the fluorescence of the probe in the absence of its
hybridization to a complementary nucleic acid. The interaction
between the fluorophore and the quencher is typically brought about
by using a nucleic acid probe sequence that forms a secondary
structure (e.g., hairpin, loop, etc.). Requiring that a probe adopt
a secondary structure significantly complicates the design of the
probe and greatly restricts the nucleic acid sequences that can be
used as components of the probes. In contrast, nucleic acid probes
using BHQs of the present invention are found to facilitate the
interaction between the quencher and the fluorophore without
requiring concomitant formation of nucleic acid secondary
structure, thereby allowing a much greater diversity of nucleic
acid sequences to be used as components of fluorescent probes.
[0019] Moreover, by varying the number and identity of the members
of the conjugated system of the BHQs, the spectral properties
(e.g., absorbance) of a BHQ can be "tuned" to match the spectral
characteristics (e.g., emission) of one or more fluorophores. For
example, as the BHQs of the present invention can be selected to
have a broad range of absorbance maxima, these quenchers are
uniquely suited for use in multiplexing applications. Furthermore,
the ability to select a BHQ having a particular spectral
characteristic allows the use of BHQs in multiplexing applications
using one or more distinct fluorophore in combination with one or
more distinct BHQ, thereby expanding the choices of donor-acceptor
pairs that can be incorporated into probes.
[0020] Thus, in a first aspect, the present invention provides a
quencher of excited state energy having a structure comprising at
least three radicals selected from substituted or unsubstituted
aryl, substituted or unsubstituted heteroaryl and combinations
thereof, wherein at least two of the residues are covalently linked
via an exocyclic diazo bond, the quencher further comprising a
reactive functional group providing a locus for conjugation of the
quencher to a carrier molecule.
[0021] In a second aspect, the present invention provides a
quencher of excited state energy having a structure according to
Formula I: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are
members independently selected from substituted or unsubstituted
aryl, substituted or unsubstituted heteroaryl and substituted or
unsubstituted unsaturated alkyl, with the proviso that at least two
of R.sup.1, R.sup.2 and R.sup.3 are members selected from
substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl. X, Y and Y' are members independently selected from
reactive functional groups; f is a number selected from 0 to 4,
inclusive, such that when (f.times.s) is greater than 1, the Y'
groups are the same or different; m is a number selected from 1 to
4, inclusive, such that when m is greater than 1, the X groups are
the same or different; n is a number from 0 to 6, inclusive, such
that when (n.times.t) is greater than 1, the Y groups are the same
or different; s is a number from 0 to 6, inclusive, such that when
s is greater than 1 the R.sup.3 groups are the same or different;
and t is a number from 1 to 6, inclusive, such that when t is
greater than 1 the R.sup.2 groups are the same or different, and
when t is 1 and s is 0, a member selected from R.sup.1, R.sup.2 and
combinations thereof is a member selected from substituted or
unsubstituted polycyclic aryl and substituted or unsubstituted
polycyclic heteroaryl groups.
[0022] In a third aspect, the present invention provides a quencher
of excited state energy having a structure according to Formula II:
##STR2## in which, X and Y are members independently selected from
reactive functional groups; m is a number selected from 1 to 5,
inclusive, such that when m is greater than 1, the X groups are the
same or different; n is a number selected from 0 to 5, inclusive,
such that when m is greater than 1, the Y groups are the same or
different; s is a number selected from 1 to 5, inclusive, such that
when s is greater than 1, the R.sup.3 groups are the same or
different. R.sup.1, R.sup.2, and R.sup.3 are members independently
selected from substituted or unsubstituted aryl, substituted or
unsubstituted heteroaryl, and substituted or unsubstituted
unsaturated alkyl, with the proviso that at least two of R.sup.1,
R.sup.2 and R.sup.3 are members independently selected from
substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl.
[0023] In each of the above-described aspects of the invention X is
preferably a member selected from --COOH, --OH and --NR'R'',
wherein R' and R'' are members independently selected from the
group consisting of H and substituted or unsubstituted alkyl
groups.
[0024] In a fourth aspect, the invention provides compounds having
a structure according to Formula IV: ##STR3## in which, X and Y are
members independently selected from reactive functional groups; m
is a number selected from 0 to 4, inclusive, such that when m is
greater than 1, the X groups are the same or different; c is a
number selected from 0 to 4, inclusive, such that when c is greater
than 1, the R.sup.3 groups are the same or different; v is a number
from 1 to 10, inclusive, more preferably from 1 to 6, inclusive and
more preferably still between 2 and 4, inclusive. When v is greater
than 1, the R.sup.2 groups are the same or different. R.sup.1,
R.sup.2, and R.sup.3 are members independently selected from
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl and substituted or unsubstituted unsaturated alkyl, with
the proviso that at least two of R.sup.1, R.sup.2 and R.sup.3 are
members selected from substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl and combinations
thereof.
[0025] In a fifth aspect, the invention provides compounds having a
structure according to Formula V: ##STR4## wherein, R.sup.5,
R.sup.6 and R.sup.7 are members independently selected from
--NR'R'', substituted or unsubstituted aryl, nitro, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, and substituted or
unsubstituted C.sub.1-C.sub.6 alkoxy, wherein R' and R'' are
independently selected from H and substituted or unsubstituted
C.sub.1-C.sub.6 alkyl. X and Y are independently selected from the
group consisting of reactive functional groups; m is a number from
1 to 2, inclusive, such that when m is 2, the X groups are the same
or different; n is a number from 0 to 1, inclusive; a is a number
from 0 to 4, inclusive, such that when a is greater than 1, the
R.sup.5 groups are the same or different; b is a number from 0 to
4, inclusive, such that when (v.times.b) is greater than 1, the
R.sup.6 groups are the same or different; c is a number from 0 to
5, inclusive, such that when c is greater than 1, the R.sup.7
groups are the same or different; and v is a number from 1 to 10,
inclusive, such that when v is greater than 1, the value of b on
each of the b phenyl rings is the same or different.
[0026] In a sixth aspect, the present invention provides a quencher
of excited state energy having a structure, which is a member
selected from: ##STR5## wherein, X.sup.5 and X.sup.6 are members
independently selected from H, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, --OR', --COOR', --NR'R'', --SH,
--OP(OX.sup.3)(N(X.sup.4).sub.2, in which R' and R'' are members
independently selected from the group consisting of H, and alkyl or
substituted alkyl, with the proviso that at least one of X.sup.5
and X.sup.6 is a reactive functional group. X.sup.3 and X.sup.4 are
members independently selected from CN, and substituted or
unsubstituted C.sub.1-C.sub.6 alkyl.
[0027] In an seventh aspect, the present invention provides a
method for determining whether a sample contains an enzyme. The
method includes: (a) contacting the sample with a peptide construct
that includes a fluorophore; (b) exciting said fluorophore; and (c)
determining a fluorescence property of said sample, wherein the
presence of said enzyme in said sample results in a change in said
fluorescence property.
[0028] Preferred peptide constructs include: i) a fluorophore; ii)
a quencher comprising at least three residues selected from aryl,
substituted aryl, heteroaryl, substituted heteroaryl and
combinations thereof, wherein at least two of the residues are
covalently linked via an exocyclic diazo bond; and iii) a cleavage
recognition site for the enzyme. Moreover, the peptide is
preferably in a conformation allowing donor-acceptor energy
transfer between the fluorophore and the quencher when the
fluorophore is excited.
[0029] In another aspect, the invention provides a method for
determining whether a compound alters an activity of an enzyme.
Preferred embodiments of this aspect of the invention include the
steps recited in connection with the above-recited aspect of the
invention and further include a step (c) determining a fluorescence
property of the sample, wherein said activity of said enzyme in
said sample results in a change in the fluorescence property.
[0030] In an ninth aspect, the present invention provides a method
for detecting a nucleic acid target sequence. The method includes:
(a) contacting the target sequence with a detector nucleic acid;
(b) hybridizing the target binding sequence to the target sequence,
thereby altering the conformation of the detector nucleic acid,
causing a change in a fluorescence parameter; and (c) detecting the
change in the fluorescence parameter, thereby detecting the nucleic
acid target sequence.
[0031] In the methods described herein, unless otherwise noted, a
preferred detector nucleic acid includes a single-stranded target
binding sequence. The binding sequence has linked thereto: i) a
fluorophore; and ii) a BHQ of the invention.
[0032] In an tenth aspect, the invention provides a method for
detecting amplification of a target sequence. The method includes
the use of an amplification reaction including the following steps:
(a) hybridizing the target sequence and a detector nucleic acid.
The detector nucleic acid includes a single-stranded target binding
sequence and an intramolecularly associated secondary structure 5'
to the target binding sequence. At least a portion of the detector
sequence forms a single stranded tail which is available for
hybridization to the target sequence; (b) extending the hybridized
detector nucleic acid on the target sequence with a polymerase to
produce a detector nucleic acid extension product and separating
the detector nucleic acid extension product from the target
sequence; (c) hybridizing a primer to the detector nucleic acid
extension product and extending the primer with the polymerase,
thereby linearizing the intramolecularly associated secondary
structure and producing a change in a fluorescence parameter; and
(d) detecting the change in the fluorescence parameter, thereby
detecting the target sequence.
[0033] In an eleventh aspect, the invention provides a method of
ascertaining whether a first nucleic acid and a second nucleic acid
hybridize. In this method, the first nucleic acid includes a BHQ
according to the invention. The method includes: (a) contacting the
first nucleic acid with the second nucleic acid; (b) detecting an
alteration in a fluorescent property of a member selected from the
first nucleic acid, the second nucleic acid and a combination
thereof, thereby ascertaining whether the hybridization occurs.
[0034] In a twelfth aspect, the present invention provides a method
for determining whether a sample contains an enzyme. The method
comprises: (a) contacting the sample with a peptide construct; (b)
exciting the fluorophore; and (c) determining a fluorescence
property of the sample, wherein the presence of the enzyme in the
sample results in a change in the fluorescence property.
[0035] Peptide constructs useful in practicing the invention
include those with the following features: i) a fluorophore; ii) a
BHQ of the invention; and iii) a cleavage recognition site for the
enzyme.
[0036] In an thirteenth aspect, the invention provides methods of
determining the amount of activity of an enzyme in a sample from an
organism. The method includes: (a) contacting a sample comprising
the enzyme and the compound with a peptide construct comprising (b)
exciting the fluorophore; and (c) determining a fluorescence
property of the sample, wherein the activity of the enzyme in the
sample results in a change in the fluorescence property. Peptide
constructs useful in this aspect of the invention are substantially
similar to those described immediately above.
[0037] In a fourteenth aspect, the invention provides a microarray
comprising a quencher of excited state energy having a structure
comprising at least three residues selected from aryl, substituted
aryl, heteroaryl, substituted heteroaryl and combinations thereof,
wherein at least two of the residues are covalently linked via an
exocyclic diazo bond. The quencher is conjugated directly to a
solid support or to a carrier molecule attached to the solid
support.
[0038] In a fifteenth aspect, the invention provides a method of
probing a microarray for the presence of a compound. The method
includes: (a) contacting the microarray with a probe interacting
with the compound. Preferred probes include a quencher of excited
state energy having a structure comprising at least three residues
selected from aryl, substituted aryl, heteroaryl, substituted
heteroaryl and combinations thereof, wherein at least two of the
residues are covalently linked via an exocyclic diazo bond; and (b)
detecting a difference in a fluorescence property of a member
selected from the probe, the compound and combinations thereof,
thereby ascertaining the presence of the compound.
[0039] In a sixteenth aspect, the present invention provides a
mixture including at least a first carrier molecule and a second
carrier molecule. The first carrier molecule has covalently bound
thereto a first quencher of excited state energy having a structure
comprising at least three residues selected from aryl, substituted
aryl, heteroaryl, substituted heteroaryl and combinations thereof,
wherein at least two of said residues are covalently linked via an
exocyclic diazo bond. The second carrier molecule has covalently
bound thereto a second quencher of excited state energy having a
structure comprising at least three residues selected from aryl,
substituted aryl, heteroaryl, substituted heteroaryl and
combinations thereof, wherein at least two of said residues are
covalently linked via an exocyclic diazo bond.
[0040] Additional objects and advantages of the present invention
will be apparent to those of skill in the art upon examination of
the detailed description that follows.
BRIEF DESCRIPTION OF THE DRAWINGS
[0041] FIG. 1 is an exemplary synthetic scheme for preparing a BHQ
of the invention.
[0042] FIG. 2 is a collection of structures of exemplary BHQs (BH1,
BH2 and BH3) of the invention.
[0043] FIG. 3 is a collection of structures of an exemplary BHQ
attached to a controlled pore glass support (BH1-CPG) and
intermediates along the synthesis of BH1-CPG.
[0044] FIG. 4 is a collection of structures of an exemplary BHQ
attached to a controlled pore glass support (BH2-CPG) and
intermediates along the synthesis of BH2-CPG.
[0045] FIG. 5 is a collection of structures of an exemplary BHQ
attached to a controlled pore glass support (BH3-CPG) and
intermediates along the synthesis of BH3-CPG.
[0046] FIG. 6 is a collection of structures of activated
derivatives of BH1.
[0047] FIG. 7(a-b) is a comparison of the absorbance spectra of
Dabcyl and the BHQs of the invention:
[0048] (a) is an overlay plot of the absorbance spectra of BH1 and
the emission spectra of three commonly used fluorophores FAM, TET
and JOE;
[0049] (b) is an overlay plot of the absorbance spectra of DABCYL
and the emission spectra of three commonly used fluorophores FAM,
TET and JOE.
[0050] FIG. 8 is a series of nucleic acid structures incorporating
exemplary BHQs of the invention.
DETAILED DESCRIPTION OF THE INVENTION AND THE PREFERRED
EMBODIMENTS
Abbreviations
[0051] "BHQ," as used herein, refers to "Black Hole Quenchers."
[0052] "FET," as used herein, refers to "Fluorescence Energy
Transfer." "FRET," as used herein, refers to "Fluorescence
Resonance Energy Transfer." These terms are used herein to refer to
both radiative and non-radiative energy transfer processes. For
example, processes in which a photon is emitted and those involving
long range electron transfer are included within these terms.
Throughout this specification, both of these phenomena are subsumed
under the general term "donor-acceptor energy transfer."
Definitions
[0053] Unless defined otherwise, all technical and scientific terms
used herein generally have the same meaning as commonly understood
by one of ordinary skill in the art to which this invention
belongs. Generally, the nomenclature used herein and the laboratory
procedures in cell culture, molecular genetics, organic chemistry
and nucleic acid chemistry and hybridization described below are
those well known and commonly employed in the art. Standard
techniques are used for nucleic acid and peptide synthesis.
Generally, enzymatic reactions and purification steps are performed
according to the manufacturer's specifications. The techniques and
procedures are generally performed according to conventional
methods in the art and various general references (see generally,
Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, 2d ed.
(1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor,
N.Y., which is incorporated herein by reference), which are
provided throughout this document. The nomenclature used herein and
the laboratory procedures in analytical chemistry, and organic
synthetic described below are those well known and commonly
employed in the art. Standard techniques, or modifications thereof,
are used for chemical syntheses and chemical analyses.
[0054] "Analyte", as used herein means any compound or molecule of
interest for which a diagnostic test is performed. An analyte can
be, for example, a protein, peptide, carbohydrate, polysaccharide,
glycoprotein, hormone, receptor, antigen, antibody, virus,
substrate, metabolite, transition state analog, cofactor,
inhibitor, drug, dye, nutrient, growth factor, etc., without
limitation.
[0055] As used herein, "energy transfer" refers to the process by
which the excited state energy of an excited group is altered by a
modifying group, such as a quencher. If the excited state
energy-modifying group is a quenching group, then the fluorescence
emission from the fluorescent group is attenuated (quenched).
Energy transfer can occur through fluorescence resonance energy
transfer, or through direct energy transfer. The exact energy
transfer mechanisms in these two cases are different. It is to be
understood that any reference to energy transfer in the instant
application encompasses all of these mechanistically-distinct
phenomena.
[0056] As used herein, "energy transfer pair" refers to any two
molecules that participate in energy transfer. Typically, one of
the molecules acts as a fluorescent group, and the other acts as a
fluorescence-modifying group. The preferred energy transfer pair of
the instant invention comprises a fluorescent group and a quenching
group of the invention. There is no limitation on the identity of
the individual members of the energy transfer pair in this
application. All that is required is that the spectroscopic
properties of the energy transfer pair as a whole change in some
measurable way if the distance between the individual members is
altered by some critical amount. "Energy transfer pair" is used to
refer to a group of molecules that form a complex within which
energy transfer occurs. Such complexes may include, for example,
two fluorescent groups, which may be different from one another and
one quenching group, two quenching groups and one fluorescent
group, or multiple fluorescent groups and multiple quenching
groups. In cases where there are multiple fluorescent groups and/or
multiple quenching groups, the individual groups may be different
from one another.
[0057] As used herein, "fluorescence-modifying group" refers to a
molecule of the invention that can alter in any way the
fluorescence emission from a fluorescent group. A
fluorescence-modifying group generally accomplishes this through an
energy transfer mechanism. Depending on the identity of the
fluorescence-modifying group, the fluorescence emission can undergo
a number of alterations, including, but not limited to,
attenuation, complete quenching, enhancement, a shift in
wavelength, a shift in polarity, and a change in fluorescence
lifetime. One example of a fluorescence-modifying group is a
quenching group.
[0058] As used herein, "quenching group" refers to any
fluorescence-modifying group of the invention that can attenuate at
least partly the light emitted by a fluorescent group. This
attenuation is referred to herein as "quenching". Hence,
illumination of the fluorescent group in the presence of the
quenching group leads to an emission signal that is less intense
than expected, or even completely absent. Quenching typically
occurs through energy transfer between the fluorescent group and
the quenching group.
[0059] As used herein, "nucleic acid" means DNA, RNA,
single-stranded, double-stranded, or more highly aggregated
hybridization motifs, and any chemical modifications thereof.
Modifications include, but are not limited to, those providing
chemical groups that incorporate additional charge, polarizability,
hydrogen bonding, electrostatic interaction, and fluxionality to
the nucleic acid ligand bases or to the nucleic acid ligand as a
whole. Such modifications include, but are not limited to, peptide
nucleic acids (PNAs), phosphodiester group modifications (e.g.,
phosphorothioates, methylphosphonates), 2'-position sugar
modifications, 5-position pyrimidine modifications, 8-position
purine modifications, modifications at exocyclic amines,
substitution of 4-thiouridine, substitution of 5-bromo or
5-iodo-uracil; backbone modifications, methylations, unusual
base-pairing combinations such as the isobases, isocytidine and
isoguanidine and the like. Nucleic acids can also include
non-natural bases, such as, for example, nitroindole. Modifications
can also include 3' and 5' modifications such as capping with a
BHQ, a fluorophore or another moiety.
[0060] "Peptide" refers to a polymer in which the monomers are
amino acids and are joined together through amide bonds,
alternatively referred to as a polypeptide. When the amino acids
are .alpha.-amino acids, either the L-optical isomer or the
D-optical isomer can be used. Additionally, unnatural amino acids,
for example, .beta.-alanine, phenylglycine and homoarginine are
also included. Commonly encountered amino acids that are not
gene-encoded may also be used in the present invention. All of the
amino acids used in the present invention may be either the D- or
L-isomer. The L-isomers are generally preferred. In addition, other
peptidomimetics are also useful in the present invention. For a
general review, see, Spatola, A. F., in CHEMISTRY AND BIOCHEMISTRY
OF AMINO ACIDS, PEPTIDES AND PROTEINS, B. Weinstein, eds., Marcel
Dekker, New York, p. 267 (1983).
[0061] "Bioactive species," refers to molecules that, when
administered to an organism, affect that organism. Exemplary
bioactive species include pharmaceuticals, pesticides, herbicides,
growth regulators and the like. Bioactive species encompasses small
molecules (i.e., approximately <1000 daltons), oligomers,
polymers and the like. Also included are nucleic acids and their
analogues, peptides and their analogues and the like.
[0062] The term "alkyl" is used herein to refer to a branched or
unbranched, saturated or unsaturated, monovalent hydrocarbon
radical, generally having from about 1-30 carbons and preferably,
from 4-20 carbons and more preferably from 6-18 carbons. When the
alkyl group has from 1-6 carbon atoms, it is referred to as a
"lower alkyl." Suitable alkyl radicals include, for example,
structures containing one or more methylene, methine and/or methyne
groups. Branched structures have a branching motif similar to
i-propyl, t-butyl, i-butyl, 2-ethylpropyl, etc. As used herein, the
term encompasses "substituted alkyls," and "cyclic alkyl."
[0063] "Substituted alkyl" refers to alkyl as just described
including one or more substituents such as, for example, lower
alkyl, aryl, acyl, halogen (i.e., alkylhalos, e.g., CF.sub.3),
hydroxy, amino, alkoxy, alkylamino, acylamino, thioamido, acyloxy,
aryloxy, aryloxyalkyl, mercapto, thia, aza, oxo, both saturated and
unsaturated cyclic hydrocarbons, heterocycles and the like. These
groups may be attached to any carbon or substituent of the alkyl
moiety. Additionally, these groups may be pendent from, or integral
to, the alkyl chain.
[0064] The term "aryl" is used herein to refer to an aromatic
substituent, which may be a single aromatic ring or multiple
aromatic rings which are fused together, linked covalently, or
linked to a common group such as a diazo, methylene or ethylene
moiety. The common linking group may also be a carbonyl as in
benzophenone. The aromatic ring(s) may include phenyl, naphthyl,
biphenyl, diphenylmethyl and benzophenone among others. The term
"aryl" encompasses "arylalkyl" and "substituted aryl."
[0065] "Substituted aryl" refers to aryl as just described
including one or more functional groups such as lower alkyl, acyl,
halogen, alkylhalos (e.g. CF.sub.3), hydroxy, amino, alkoxy,
alkylamino, acylamino, acyloxy, phenoxy, mercapto and both
saturated and unsaturated cyclic hydrocarbons which are fused to
the aromatic ring(s), linked covalently or linked to a common group
such as a diazo, methylene or ethylene moiety. The linking group
may also be a carbonyl such as in cyclohexyl phenyl ketone. The
term "substituted aryl" encompasses "substituted arylalkyl."
[0066] The term "arylalkyl" is used herein to refer to a subset of
"aryl" in which the aryl group is attached to another group by an
alkyl group as defined herein.
[0067] "Substituted arylalkyl" defines a subset of "substituted
aryl" wherein the substituted aryl group is attached to another
group by an alkyl group as defined herein.
[0068] The term "acyl" is used to describe a ketone substituent,
--C(O)R, where R is alkyl or substituted alkyl, aryl or substituted
aryl as defined herein.
[0069] The term "halogen" is used herein to refer to fluorine,
bromine, chlorine and iodine atoms.
[0070] The term "hydroxy" is used herein to refer to the group
--OH.
[0071] The term "amino" is used to --NRR', wherein R and R' are
independently H, alkyl, aryl or substituted analogues thereof.
"Amino" encompasses "alkylamino" denoting secondary and tertiary
amines and "acylamino" describing the group RC(O)NR'.
[0072] The term "alkoxy" is used herein to refer to the --OR group,
where R is alkyl, or a substituted analogue thereof. Suitable
alkoxy radicals include, for example, methoxy, ethoxy, t-butoxy,
etc.
[0073] As used herein, the term "aryloxy" denotes aromatic groups
that are linked to another group directly through an oxygen atom.
This term encompasses "substituted aryloxy" moieties in which the
aromatic group is substituted as described above for "substituted
aryl." Exemplary aryloxy moieties include phenoxy, substituted
phenoxy, benzyloxy, phenethyloxy, etc.
[0074] As used herein "aryloxyalkyl" defines aromatic groups
attached, through an oxygen atom to an alkyl group, as defined
herein. The term "aryloxyalkyl" encompasses "substituted
aryloxyalkyl" moieties in which the aromatic group is substituted
as described for "substituted aryl."
[0075] As used herein, the term "mercapto" defines moieties of the
general structure --S--R wherein R is H, alkyl, aryl or
heterocyclic as described herein.
[0076] The term "saturated cyclic hydrocarbon" denotes groups such
as the cyclopropyl, cyclobutyl, cyclopentyl, etc., and substituted
analogues of these structures. These cyclic hydrocarbons can be
single- or multi-ring structures.
[0077] The term "unsaturated cyclic hydrocarbon" is used to
describe a monovalent non-aromatic group with at least one double
bond, such as cyclopentene, cyclohexene, etc. and substituted
analogues thereof. These cyclic hydrocarbons can be single- or
multi-ring structures.
[0078] The term "heteroaryl" as used herein refers to aromatic
rings in which one or more carbon atoms of the aromatic ring(s) are
replaced by a heteroatom such as nitrogen, oxygen or sulfur.
Heteroaryl refers to structures that may be a single aromatic ring,
multiple aromatic ring(s), or one or more aromatic rings coupled to
one or more non-aromatic ring(s). In structures having multiple
rings, the rings can be fused together, linked covalently, or
linked to a common group such as a diazo, methylene or ethylene
moiety. The common linking group may also be a carbonyl as in
phenyl pyridyl ketone. As used herein, rings such as thiophene,
pyridine, isoxazole, phthalimide, pyrazole, indole, furan, etc. or
benzo-fused analogues of these rings are defined by the term
"heteroaryl."
[0079] "Heteroarylalkyl" defines a subset of "heteroaryl" wherein
an alkyl group, as defined herein, links the heteroaryl group to
another group.
[0080] "Substituted heteroaryl" refers to heteroaryl as just
described wherein the heteroaryl nucleus is substituted with one or
more functional groups such as lower alkyl, acyl, halogen,
alkylhalos (e.g. CF.sub.3), hydroxy, amino, alkoxy, alkylamino,
acylamino, acyloxy, mercapto, etc. Thus, substituted analogues of
heteroaromatic rings such as thiophene, pyridine, isoxazole,
phthalimide, pyrazole, indole, furan, etc. or benzo-fused analogues
of these rings are defined by the term "substituted
heteroaryl."
[0081] "Substituted heteroarylalkyl" refers to a subset of
"substituted heteroaryl" as described above in which an alkyl
group, as defined herein, links the heteroaryl group to another
group.
[0082] The term "heterocyclic" is used herein to describe a
monovalent saturated or unsaturated non-aromatic group having a
single ring or multiple condensed rings from 1-12 carbon atoms and
from 1-4 heteroatoms selected from nitrogen, sulfur or oxygen
within the ring. Such heterocycles are, for example,
tetrahydrofuran, morpholine, piperidine, pyrrolidine, etc.
[0083] The term "substituted heterocyclic" as used herein describes
a subset of "heterocyclic" wherein the heterocycle nucleus is
substituted with one or more functional groups such as lower alkyl,
acyl, halogen, alkylhalos (e.g CF.sub.3), hydroxy, amino, alkoxy,
alkylamino, acylamino, acyloxy, mercapto, etc.
[0084] The term "heterocyclicalkyl" defines a subset of
"heterocyclic" wherein an alkyl group, as defined herein, links the
heterocyclic group to another group.
Introduction
[0085] The present invention provides a class of fluorescence
modifiers, particularly quenchers, of excited state energy. The
compounds of the invention absorb excited state energy from a
reporter fluorophore, but are themselves substantially
non-fluorescent. The fluorophore transferring the excited state
energy to the quenchers of the invention will generally be a label
that is attached to an analyte or a species that interacts with,
and allows detection and/or quantification of the analyte.
[0086] Fluorescent labels have the advantage of requiring few
precautions in handling, and being amenable to high-throughput
visualization techniques (optical analysis including digitization
of the image for analysis in an integrated system comprising a
computer). Preferred labels are typically characterized by one or
more of the following: high sensitivity, high stability, low
background, low environmental sensitivity and high specificity in
labeling. Many fluorescent labels are commercially available from
the SIGMA chemical company (Saint Louis, Mo.), Molecular Probes
(Eugene, Oreg.), R&D systems (Minneapolis, Minn.), Pharmacia
LKB Biotechnology (Piscataway, N.J.), CLONTECH Laboratories, Inc.
(Palo Alto, Calif.), Chem Genes Corp., Aldrich Chemical Company
(Milwaukee, Wis.), Glen Research, Inc., GIBCO BRL Life
Technologies, Inc. (Gaithersburg, Md.), Fluka Chemica-Biochemika
Analytika (Fluka Chemie AG, Buchs, Switzerland), and Applied
Biosystems (Foster City, Calif.), as well as many other commercial
sources known to one of skill. Furthermore, those of skill in the
art will recognize how to select an appropriate fluorophore for a
particular application and, if it not readily available
commercially, will be able to synthesize the necessary fluorophore
de novo or synthetically modify commercially available fluorescent
compounds to arrive at the desired fluorescent label.
[0087] In addition to small molecule fluorophores, naturally
occurring fluorescent proteins and engineered analogues of such
proteins are useful in the present invention. Such proteins
include, for example, green fluorescent proteins of cnidarians
(Ward et al., Photochem. Photobiol. 35:803-808 (1982); Levine et
al., Comp. Biochem. Physiol., 72B:77-85 (1982)), yellow fluorescent
protein from Vibrio fischeri strain (Baldwin et al., Biochemistry
29:5509-15 (1990)), Peridinin-chlorophyll from the dinoflagellate
Symbiodinium sp. (Morris et al., Plant Molecular Biology 24:673:77
(1994)), phycobiliproteins from marine cyanobacteria, such as
Synechococcus, e.g., phycoerythrin and phycocyanin (Wilbanks et
al., J. Biol. Chem. 268:1226-35 (1993)), and the like.
[0088] The compounds, probes and methods discussed in the following
sections are generally representative of the compositions of the
invention and the methods in which such compositions can be used.
The following discussion is intended as illustrative of selected
aspects and embodiments of the present invention and it should not
be interpreted as limiting the scope of the present invention.
Black Hole Quenchers
[0089] The present invention provides a family of dark quenchers
that are referred to herein as "Black Hole Quenchers.TM." ("BHQ"s).
The quenchers of the invention include conjugated .pi.-bonded
systems that are preferably azo-linked aromatic species.
[0090] In a first aspect, the present invention provides a quencher
of excited state energy having a structure comprising at least
three radicals selected from substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl and combinations thereof,
wherein at least two of the residues are covalently linked via an
exocyclic diazo bond, the quencher further comprising a reactive
functional group providing a locus for conjugation of the quencher
to a carrier molecule. Although the quenchers can be used in their
free unbound form, it is generally preferred that they be tethered
to another species, thus, preferred quenchers further comprise a
reactive functional group that provides a locus for conjugation of
the quencher to a carrier molecule.
[0091] In another preferred embodiment, the BHQs of the invention
described herein have substantially no native fluorescence,
particularly near their absorbance maxima or near the absorbance
maxima of fluorophores used in conjunction with the BHQs. The BHQs
will preferably have an absorbance maximum of from about 400 nm to
about 760 nm, and more preferably, of from about 500 nm to about
600 nm.
[0092] In a second aspect, the present invention provides a
quencher of excited state energy having a structure according to
Formula I: ##STR6## wherein R.sup.1, R.sup.2 and R.sup.3 are
members independently selected from substituted or unsubstituted
aryl, substituted or unsubstituted heteroaryl and substituted or
unsubstituted unsaturated alkyl, with the proviso that at least two
of R.sup.1, R.sup.2 and R.sup.3 are members selected from
substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl. X, Y and Y' are members independently selected from
reactive functional groups; f is a number selected from 0 to 4,
inclusive, such that when (f.times.s) is greater than 1, the Y'
groups are the same or different; m is a number selected from 1 to
4, inclusive, such that when m is greater than 1, the X groups are
the same or different; n is a number from 0 to 6, inclusive, such
that when (n.times.t) is greater than 1, the Y groups are the same
or different; s is a number from 0 to 6, inclusive, such that when
s is greater than 1 the R.sup.3 groups are the same or different;
and t is a number from 1 to 6, inclusive, such that when t is
greater than 1 the R.sup.2 groups are the same or different, and
when t is 1 and s is 0, a member selected from R.sup.1, R.sup.2 and
combinations thereof is a member selected from substituted or
unsubstituted polycyclic aryl and substituted or unsubstituted
polycyclic heteroaryl groups.
[0093] In a third aspect, the present invention provides a quencher
of excited state energy having a structure according to Formula II:
##STR7## in which, X and Y are members independently selected from
reactive functional groups; m is a number selected from 1 to 5,
inclusive, such that when m is greater than 1, the X groups are the
same or different; n is a number selected from 0 to 5, inclusive,
such that when m is greater than 1, the Y groups are the same or
different; s is a number selected from 1 to 5, inclusive, such that
when s is greater than 1, the R.sup.3 groups are the same or
different. R.sup.1, R.sup.2, and R.sup.3 are members independently
selected from substituted or unsubstituted aryl, substituted or
unsubstituted heteroaryl, and substituted or unsubstituted
unsaturated alkyl, with the proviso that at least two of R.sup.1,
R.sup.2 and R.sup.3 are members independently selected from
substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl.
[0094] In a preferred embodiment, m is 1; n is 0; c is 1; and
R.sup.1, R.sup.2 and R.sup.3 are members independently selected
from aryl and substituted aryl.
[0095] In a preferred embodiment of each of the above-described
aspects of the invention, R.sup.1, R.sup.2 and R.sup.3 are members
independently selected from aryl and aryl substituted with a member
selected from amino, amino derivatives, nitro, C.sub.1-C.sub.6
alkyl, C.sub.1-C.sub.6 alkoxy and combinations thereof, and still
more preferably, R.sup.1 includes a structure according to Formula
III: ##STR8## wherein R.sup.4 is a member selected from alkyl,
substituted alkyl, aryl, substituted aryl, heteroaryl and
substituted heteroaryl.
[0096] In a fourth aspect, the invention provides compounds having
a structure according to Formula IV: ##STR9## in which, X and Y are
members independently selected from reactive functional groups; m
is a number selected from 0 to 4, inclusive, such that when m is
greater than 1, the X groups are the same or different; c is a
number selected from 0 to 4, inclusive, such that when c is greater
than 1, the R.sup.3 groups are the same or different; v is a number
from 1 to 10, inclusive, more preferably from 1 to 6, inclusive and
more preferably still between 2 and 4, inclusive. When v is greater
than one the R.sup.2 groups are the same or different. R.sup.1,
R.sup.2, and R.sup.3 are members independently selected from
substituted or unsubstituted aryl, substituted or unsubstituted
heteroaryl and substituted or unsubstituted unsaturated alkyl, with
the proviso that at least two of R.sup.1, R.sup.2 and R.sup.3 are
members selected from substituted or unsubstituted aryl,
substituted or unsubstituted heteroaryl and combinations
thereof.
[0097] In a fifth aspect, the invention provides compounds having a
structure according to Formula V: ##STR10## wherein, R.sup.5,
R.sup.6 and R.sup.7 are members independently selected from
--NR'R'', substituted or unsubstituted aryl, nitro, substituted or
unsubstituted C.sub.1-C.sub.6 alkyl, and substituted or
unsubstituted C.sub.1-C.sub.6 alkoxy, wherein R' and R'' are
independently selected from H and substituted or unsubstituted
C.sub.1-C.sub.6 alkyl. X and Y are independently selected from the
group consisting of reactive functional groups; n is a number from
0 to 1, inclusive; a is a number from 0 to 4, inclusive, such that
when a is greater than 1, the R.sup.5 groups are the same or
different; b is a number from 0 to 4, inclusive, such that when
(v.times.b) is greater than 1, the R.sup.6 groups are the same or
different; c is a number from 0 to 5, inclusive, such that when c
is greater than 1, the R.sup.7 groups are the same or different;
and v is a number from 1 to 10, inclusive, such that when v is
greater than 1, the value of b on each of the v phenyl rings is the
same or different.
[0098] In a preferred embodiment, the present invention provides a
quencher of excited state energy having a structure according to
Formula VI: ##STR11## wherein, R.sup.5, R.sup.6 and R.sup.7 are
members independently selected from amine, alkyl amine, substituted
or unsubstituted aryl, nitro, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, substituted or unsubstituted C.sub.1-C.sub.6
alkoxy; a is a number between 0 and 5, inclusive, such that when a
is greater than 1, the R.sup.5 groups are the same or different; b
is a number between 0 and 4, inclusive, such that when b is greater
than 1, the R.sup.6 groups are the same or different; c is a number
between 0 and 4, inclusive, such that when c is greater than 1, the
R.sup.7 groups are the same or different; and X.sup.1 and X.sup.2
are members independently selected from C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 substituted alkyl, --OH , --COOH, --NR'R'', --SH,
--OP(OX.sup.3)(N(R'R'').sub.2, in which R' and R'' are members
independently selected from the group consisting of H, and alkyl or
substituted alkyl.
[0099] In a sixth aspect, the present invention provides a quencher
of excited state energy having a structure, which is a member
selected from: ##STR12## X.sup.5 and X.sup.6 are members
independently selected from H, substituted or unsubstituted
C.sub.1-C.sub.6 alkyl, --OR', --COOR', --NR'R'', --SH,
--OP(OX.sup.3)(N(X.sup.4).sub.2, in which R' and R'' are members
independently selected from the group consisting of H, and alkyl or
substituted alkyl. At least one of X.sup.5 and X.sup.6 is a
reactive functional group. X.sup.3 and X.sup.4 are members
independently selected from CN, and substituted or unsubstituted
C.sub.1-C.sub.6 alkyl.
[0100] The following discussion is generally relevant to the
identity of the reactive groups of the compounds of the invention
and is particularly relevant to the groups X, X.sup.1 and X.sup.2
in each of the above-described aspects of the invention.
[0101] In a preferred embodiment, X is a member selected from
amine, alkyl amine, substituted alkyl amine, and aryl amine groups,
more preferably X has a structure according to Formula VII:
##STR13## wherein, R.sup.9 and R.sup.10 are members independently
selected from alkyl and substituted alkyl; and X.sup.1 and X.sup.2
are members independently selected from --CH.sub.3, --OH, --COOH,
--NH.sub.2, --SH, --OP(OX.sup.3)(N(X.sup.4).sub.2).sub.2 wherein,
X.sup.3 and X.sup.4 are members independently selected from alkyl
and substituted alkyl, and preferably X.sup.3 is cyanoethyl; and
X.sup.4 is isopropyl.
[0102] In another preferred embodiment, a member selected from
R.sup.9, R.sup.10 and combinations thereof comprises a polyether.
Preferred polyethers include, for example, poly(ethylene glycol),
poly(propyleneglycol) and copolymers thereof.
[0103] In a further preferred embodiment, X has a structure
according to Formula VIII: ##STR14## wherein, X.sup.1, X.sup.2,
X.sup.3 and X.sup.4 are substantially as described above and p and
q are numbers independently selected from 1 to 20, inclusive,
preferably from 2 to 16, inclusive.
[0104] The compounds of the invention can be prepared as a single
isomer or a mixture of isomers, including, for example cis-isomers,
trans-isomers, diastereomers and stereoisomers. In a preferred
embodiment, the compounds are prepared as substantially a single
isomer. Isomerically pure compounds are prepared by using synthetic
intermediates that are isomerically pure in combination with
reactions that either leave the stereochemistry at a chiral center
unchanged or result in its complete inversion. Alternatively, the
final product or intermediates along the synthetic route can be
resolved into a single isomer. Techniques for inverting or leaving
unchanged a particular stereocenter, and those for resolving
mixtures of stereoisomers are well known in the art and it is well
within the ability of one of skill in the art to choose an
appropriate resolution or synthetic method for a particular
situation. See, generally, Fumiss et al. (eds.), VOGEL'S
ENCYCLOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5.sup.TH ED., Longman
Scientific and Technical Ltd., Essex, 1991, pp. 809-816; and
Heller, Acc. Chem. Res. 23: 128 (1990).
Reactive Functional Groups
[0105] The compounds of the invention bear a reactive functional
group, which can be located at any position on an aryl nucleus or
on a chain, such as an alkyl chain, attached to an aryl nucleus.
When the reactive group is attached to an alkyl, or substituted
alkyl chain tethered to an aryl nucleus, the reactive group is
preferably located at a terminal position of an alkyl chain.
Reactive groups and classes of reactions useful in practicing the
present invention are generally those that are well known in the
art of bioconjugate chemistry. Currently favored classes of
reactions available with reactive BHQs are those which proceed
under relatively mild conditions. These include, but are not
limited to nucleophilic substitutions (e.g., reactions of amines
and alcohols with acyl halides, active esters), electrophilic
substitutions (e.g., enamine reactions) and additions to
carbon-carbon and carbon-heteroatom multiple bonds (e.g., Michael
reaction, Diels-Alder addition). These and other useful reactions
are discussed in, for example, March, ADVANCED ORGANIC CHEMISTRY,
3rd Ed., John Wiley & Sons, New York, 1985; Hermanson,
BIOCONJUGATE TECHNIQUES, Academic Press, San Diego, 1996; and
Feeney et al., MODIFICATION OF PROTEINS; Advances in Chemistry
Series, Vol. 198, American Chemical Society, Washington, D.C.,
1982.
[0106] Useful reactive functional groups include, for example:
[0107] (a) carboxyl groups and various derivatives thereof
including, but not limited to, N-hydroxysuccinimide esters,
N-hydroxybenztriazole esters, acid halides, acyl imidazoles,
thioesters, p-nitrophenyl esters, alkyl, alkenyl, alkynyl and
aromatic esters; [0108] (b) hydroxyl groups, which can be converted
to esters, ethers, aldehydes, etc. [0109] (c) haloalkyl groups,
wherein the halide can be later displaced with a nucleophilic group
such as, for example, an amine, a carboxylate anion, thiol anion,
carbanion, or an alkoxide ion, thereby resulting in the covalent
attachment of a new group at the site of the halogen atom; [0110]
(d) dienophile groups, which are capable of participating in
Diels-Alder reactions such as, for example, maleimido groups;
[0111] (e) aldehyde or ketone groups, such that subsequent
derivatization is possible via formation of carbonyl derivatives
such as, for example, imines, hydrazones, semicarbazones or oximes,
or via such mechanisms as Grignard addition or alkyllithium
addition; [0112] (f) sulfonyl halide groups for subsequent reaction
with amines, for example, to form sulfonamides; [0113] (g) thiol
groups, which can be, for example, converted to disulfides or
reacted with acyl halides; [0114] (h) amine or sulfhydryl groups,
which can be, for example, acylated, alkylated or oxidized; [0115]
(i) alkenes, which can undergo, for example, cycloadditions,
acylation, Michael addition, etc; [0116] (j) epoxides, which can
react with, for example, amines and hydroxyl compounds; and [0117]
(k) phosphoramidites and other standard functional groups useful in
nucleic acid synthesis.
[0118] The reactive functional groups can be chosen such that they
do not participate in, or interfere with, the reactions necessary
to assemble the reactive BHQ analogue. Alternatively, a reactive
functional group can be protected from participating in the
reaction by the presence of a protecting group. Those of skill in
the art understand how to protect a particular functional group
such that it does not interfere with a chosen set of reaction
conditions. For examples of useful protecting groups, see, for
example, Greene et al., PROTECTIVE GROUPS IN ORGANIC SYNTHESIS,
John Wiley & Sons, New York, 1991.
Donor and Acceptor Moieties
[0119] One of the advantages of the compounds of the invention is
that a wide range of energy donor molecules can be used in
conjunction with the BHQs. A vast array of fluorophores are known
to those of skill in the art. See, for example, Cardullo et al.,
Proc. Natl. Acad. Sci. USA 85: 8790-8794 (1988); Dexter, D. L., J.
of Chemical Physics 21: 836-850 (1953); Hochstrasser et al.,
Biophysical Chemistry 45: 133-141 (1992); Selvin, P., Methods in
Enzymology 246: 300-334 (1995); Steinberg, I. Ann. Rev. Biochem.,
40: 83-114 (1971); Stryer, L. Ann. Rev. Biochem., 47: 819-846
(1978); Wang et al., Tetrahedron Letters 31: 6493-6496 (1990); Wang
et al., Anal. Chem. 67: 1197-1203 (1995).
[0120] A non-limiting list of exemplary donors that can be used in
conjunction with the quenchers of the invention is provided in
Table 1. TABLE-US-00001 TABLE 1 Suitable moieties that can be
selected as donors or acceptors in donor-acceptor energy transfer
pairs 4-acetamido-4'-isothiocyanatostilbene-2,2'disulfonic acid
acridine and derivatives: acridine acridine isothiocyanate
5-(2'-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS)
4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate
N-(4-anilino-1-naphthyl)maleimide anthranilamide BODIPY Brilliant
Yellow coumarin and derivatives: coumarin 7-amino-4-methylcoumarin
(AMC, Coumarin 120) 7-amino-4-trifluoromethylcouluarin (Coumaran
151) cyanine dyes cyanosine 4',6-diaminidino-2-phenylindole (DAPI)
5', 5''-dibromopyrogallol-sulfonaphthalein (Bromopyrogallol Red)
7-diethylamino-3-(4'-isothiocyanatophenyl)-4-methylcoumarin
diethylenetriamine pentaacetate
4,4'-diisothiocyanatodihydro-stilbene-2,2'-disulfonic acid
4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid
5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS,
dansylchloride) 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL)
4-dimethylaminophenylazophenyl-4'-isothiocyanate (DABITC) eosin and
derivatives: eosin eosin isothiocyanate erythrosin and derivatives:
erythrosin B erythrosin isothiocyanate ethidium fluorescein and
derivatives: 5-carboxyfluorescein (FAM)
5-(4,6-dichlorotriazin-2-yl)aminofluorescein (DTAF)
2',7'-dimethoxy-4'5'-dichloro-6-carboxyfluorescein (JOE)
fluorescein fluorescein isothiocyanate QFITC (XRITC) fluorescamine
IR144 IR1446 Malachite Green isothiocyanate 4-methylumbelliferone
ortho cresolphthalein nitrotyrosine pararosaniline Phenol Red
B-phycoerythrin o-phthaldialdehyde pyrene and derivatives: pyrene
pyrene butyrate succinimidyl 1-pyrene butyrate quantum dots
Reactive Red 4 (Cibacron .TM. Brilliant Red 3B-A) rhodamine and
derivatives: 6-carboxy-X-rhodamine (ROX) 6-carboxyrhodamine (R6G)
lissamine rhodamine B sulfonyl chloride rhodamine (Rhod) rhodamine
B rhodamine 123 rhodamine X isothiocyanate sulforhodamine B
sulforhodamine 101 sulfonyl chloride derivative of sulforhodamine
101 (Texas Red) N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA)
tetramethyl rhodamine tetramethyl rhodamine isothiocyanate (TRITC)
riboflavin rosolic acid terbium chelate derivatives
[0121] There is a great deal of practical guidance available in the
literature for selecting appropriate donor-acceptor pairs for
particular probes, as exemplified by the following references:
Pesce et al., Eds., FLUORESCENCE SPECTROSCOPY (Marcel Dekker, New
York, 1971); White et al., FLUORESCENCE ANALYSIS: A PRACTICAL
APPROACH (Marcel Dekker, New York, 1970); and the like. The
literature also includes references providing exhaustive lists of
fluorescent and chromogenic molecules and their relevant optical
properties for choosing reporter-quencher pairs (see, for example,
Berlman, HANDBOOK OF FLUORESCENCE SPECTRA OF AROMATIC MOLECULES,
2nd Edition (Academic Press, New York, 1971); Griffiths, COLOUR AND
CONSTITUTION OF ORGANIC MOLECULES (Academic Press, New York, 1976);
Bishop, Ed., INDICATORS (Pergamon Press, Oxford, 1972); Haugland,
HANDBOOK OF FLUORESCENT PROBES AND RESEARCH CHEMICALS (Molecular
Probes, Eugene, 1992) Pringsheim, FLUORESCENCE AND PHOSPHORESCENCE
(Interscience Publishers, New York, 1949); and the like. Further,
there is extensive guidance in the literature for derivatizing
reporter and quencher molecules for covalent attachment via common
reactive groups that can be added to a nucleic acid, as exemplified
by the following references: Haugland (supra); Ullman et al., U.S.
Pat. No. 3,996,345; Khanna et al., U.S. Pat. No. 4,351,760. Thus,
it is well within the abilities of those of skill in the art to
choose an energy exchange pair for a particular application and to
conjugate the members of this pair to a probe molecule, such as,
for example, a nucleic acid, peptide or other polymer.
[0122] Generally, it is preferred that an absorbance band of the
BHQ substantially overlap the fluorescence emission band of the
donor. When the donor (fluorophore) is a component of a probe that
utilizes donor-acceptor energy transfer, the donor fluorescent
moiety and the quencher (acceptor) of the invention are preferably
selected so that the donor and acceptor moieties exhibit
donor-acceptor energy transfer when the donor moiety is excited.
One factor to be considered in choosing the fluorophore-quencher
pair is the efficiency of donor-acceptor energy transfer between
them. Preferably, the efficiency of FRET between the donor and
acceptor moieties is at least 10%, more preferably at least 50% and
even more preferably at least 80%. The efficiency of FRET can
easily be empirically tested using the methods both described
herein and known in the art.
[0123] The efficiency of energy transfer between the donor-acceptor
pair can also be adjusted by changing the ability of the donor and
acceptor groups to dimerize or closely associate. If the donor and
acceptor moieties are known or determined to closely associate, an
increase or decrease in association can be promoted by adjusting
the length of a linker moiety, or of the probe itself, between the
donor and acceptor. The ability of donor-acceptor pair to associate
can be increased or decreased by tuning the hydrophobic or ionic
interactions, or the steric repulsions in the probe construct.
Thus, intramolecular interactions responsible for the association
of the donor-acceptor pair can be enhanced or attenuated. Thus, for
example, the association between the donor-acceptor pair can be
increased by, for example, utilizing a donor bearing an overall
negative charge and an acceptor with an overall positive
charge.
[0124] In addition to fluorophores that are attached directly to a
probe, the fluorophores can also be attached by indirect means. In
this embodiment, a ligand molecule (e.g., biotin) is generally
covalently bound to the probe species. The ligand then binds to
another molecules (e.g., streptavidin) molecule, which is either
inherently detectable or covalently bound to a signal system, such
as a fluorescent compound, or an enzyme that produces a fluorescent
compound by conversion of a non-fluorescent compound. Useful
enzymes of interest as labels include, for example, hydrolases,
particularly phosphatases, esterases and glycosidases, hydrolases,
peptidases or oxidases, particularly peroxidases, and Fluorescent
compounds include fluorescein and its derivatives, rhodamine and
its derivatives, dansyl, umbelliferone, etc., as discussed above.
For a review of various labeling or signal producing systems that
can be used, see, U.S. Pat. No. 4,391,904.
[0125] Presently preferred donors of use in conjunction with BHQ,
include, for example, xanthene dyes, including fluoresceins,
cyanine dyes and rhodamine dyes. Many suitable forms of these
compounds are widely available commercially with substituents on
their phenyl moieties, which can be used as the site for bonding or
as the bonding functionality for attachment to an nucleic acid.
Another group of preferred fluorescent compounds are the
naphthylamines, having an amino group in the alpha or beta
position. Included among such naphthylamino compounds are
1-dimethylaminonaphthyl-5-sulfonate, 1-anilino-8-naphthalene
sulfonate and 2-p-touidinyl-6-naphthalene sulfonate. Other donors
include 3-phenyl-7-isocyanatocoumarin, acridines, such as
9-isothiocyanatoacridine and acridine orange;
N-(p-(2-benzoxazolyl)phenyl)maleimide; benzoxadiazoles, stilbenes,
pyrenes, and the like.
[0126] For clarity of illustration, the discussion below focuses on
attaching BHQs and fluorophores to nucleic acids. The focus on
nucleic acid probes is not intended to limit the scope of probe
molecules to which BHQs can be attached. Those of skill in the art
will appreciate that BHQs can also be attached to small molecules,
proteins, peptides, synthetic polymers, solid supports and the like
using standard synthetic chemisty.
[0127] In a presently preferred embodiment, in which the probe is a
nucleic acid probe, the reporter molecule is a fluorescein dye
(FAM). The fluorescein moiety is preferably attached to either the
3'- or the 5'-terminus of the nucleic acid, although internal sites
are also accessible and have utility for selected purposes.
Whichever terminus the FAM derivative is attached to, the BHQ will
generally be attached to its antipode, or at a position internal to
the nucleic acid chain. The FAM donor is preferably introduced
using a 6-FAM amidite. Different donor groups are also preferably
introduced using an amidite derivative of the donor. Alternatively,
donor groups comprising reactive groups (e.g., isothiocyanates,
active esters, etc.) can be introduced via reaction with a reactive
moiety on a tether or linker arm attached to the nucleic acid
(e.g., hexyl amine).
[0128] In yet another preferred embodiment, the donor moiety can be
attached at the 3'-terminus of a nucleic acid by the use of a
derivatized synthesis support. For example, TAMRA
(tetramethylrhodamine carboxylic acid) is attached to a nucleic
acid 3'-terminus using a solid support that is derivatized with an
analogue of this fluorophore (Biosearch Technologies, Inc.)
[0129] In view of the well-developed body of literature concerning
the conjugation of small molecules to nucleic acids, many other
methods of attaching donor/acceptor pairs to nucleic acids will be
apparent to those of skill in the art. For example, rhodamine and
fluorescein dyes are conveniently attached to the 5'-hydroxyl of an
nucleic acid at the conclusion of solid phase synthesis by way of
dyes derivatized with a phosphoramidite moiety (see, for example,
Woo et al., U.S. Pat. No. 5,231,191; and Hobbs, Jr., U.S. Pat. No.
4,997,928).
[0130] More specifically, there are many linking moieties and
methodologies for attaching groups to the 5'- or 3'-termini of
nucleic acids, as exemplified by the following references:
Eckstein, editor, Nucleic acids and Analogues: A Practical Approach
(IRL Press, Oxford, 1991); Zuckerman et al., Nucleic Acids
Research, 15: 5305-5321 (1987) (3'-thiol group on nucleic acid);
Sharma et al., Nucleic Acids Research, 19: 3019 (1991)
(3'-sulfhydryl); Giusti et al., PCR Methods and Applications, 2:
223-227 (1993) and Fung et al., U.S. Pat. No. 4,757,141
(5'-phosphoamino group via Aminolink TM II available from P.E.
Biosystems, CA.) Stabinsky, U.S. Pat. No. 4,739,044
(3-aminoalkylphosphoryl group); Agrawal et al., Tetrahedron
Letters, 31: 1543-1546 (1990) (attachment via phosphoramidate
linkages); Sproat et al., Nucleic Acids Research, 15: 4837 (1987)
(5-mercapto group); Nelson et al., Nucleic Acids Research, 17:
7187-7194 (1989) (3'-amino group), and the like.
[0131] Means of detecting fluorescent labels are well known to
those of skill in the art. Thus, for example, fluorescent labels
can be detected by exciting the fluorophore with the appropriate
wavelength of light and detecting the resulting fluorescence. The
fluorescence can be detected visually, by means of photographic
film, by the use of electronic detectors such as charge coupled
devices (CCDs) or photomultipliers and the like. Similarly,
enzymatic labels may be detected by providing the appropriate
substrates for the enzyme and detecting the resulting reaction
product.
Synthesis
[0132] The compounds of the invention are synthesized by an
appropriate combination of generally well-known synthetic methods.
Techniques useful in synthesizing the compounds of the invention
are both readily apparent and accessible to those of skill in the
relevant art. The discussion below is offered to illustrate certain
of the diverse methods available for use in assembling the
compounds of the invention, it is not intended to define the scope
of reactions or reaction sequences that are useful in preparing the
compounds of the present invention.
[0133] One method of synthesizing compounds of the invention is set
forth in Scheme 1 (FIG. 1). Scheme 1 is a generalized schematic of
one synthetic scheme useful with the BHQs of the invention. An
azido derivative of a dye is coupled to an aryl derivative 1, at pH
9, forming the corresponding diazo adduct 2. The diol 2 is
monoprotected with a group, such as the dimethoxytrityl group to
form compound 3, having one free hydroxyl moiety. Compound 3 is
converted to phosphoramidite 4 by contacting it with an agent, such
as 2-cyanoethyl diisopropylchlorophosphoramidite in the presence of
a mildly acidic activator, such as tetrazole. The phosphoramidite
is coupled to a hydroxyl-bearing controlled pore glass support and
subsequently oxidized to the corresponding phosphotriester
derivative, thereby forming an appropriate starting material, 5,
for the synthesis of an array of nucleic acids derivatized at the
3'-position with a BHQ.
[0134] The above-recited synthetic scheme is intended to be
exemplary of one embodiment of the invention, those of skill in the
art will recognize that many other synthetic strategies employing
reactive BHQ analogues are available. For example, by a slight
modification of the method above, a derivative appropriate for
modification of a nucleic acid at the 5'-position is easily
accessible. In an alternative scheme, compound 4, is not tethered
to a solid support, but is added as the final subunit during
nucleic acid synthesis, to prepare a nucleic acid with a 5'-BHQ
group.
[0135] The above-described synthetic scheme can be practiced using
a variety of BHQ compounds of the invention, such as those set
forth in FIG. 2. FIG. 2 provides the structures of three exemplary
BHQs, BH1 (6), BH2 (10) and BH3 (14).
[0136] FIG. 3 sets forth the structures of a phosphoramidite (8) of
BH1 (7), and a derivative of BH1, which is tethered to a controlled
pore glass support (9). Both the phosphoramidite and the CPG
conjugate can be prepared by art-recognized methods, including
those set forth herein. Similarly, FIG. 4 sets forth the structures
of a phosphoramidite (12) of BH2 (11), and a derivative of BH2,
which is tethered to a controlled pore glass support (13) and FIG.
5 sets forth the structures of a phosphoramidite (16) of BH1 (15),
and a derivative of BH3, which is tethered to a controlled pore
glass support (17).
[0137] In a still further modification of the scheme of FIG. 1,
compound 4 is coupled to a nucleic acid intermediate between the
3'- and 5'-positions, the DMT group is removed using standard
nucleic acid chemistry, or a modification thereof, and a nucleic
acid subunit is tethered to the deprotected primary hydroxyl group
as though the hydroxyl group were the 5'-hydroxyl of a preceding
nucleic acid subunit, thereby providing a nucleic acid having a BHQ
moiety at an internal position.
Assays and BHO-Bearing Probes
[0138] In another preferred embodiment, the present invention
provides a BHQ that is tethered to another molecule, such as a
probe molecule and assays using these probes.
Assays
[0139] The following discussion is generally relevant to the assays
described herein. This discussion is intended to illustrate the
invention by reference to certain preferred embodiments and should
not be interpreted as limiting the scope of probes and assay types
in which the compounds of the invention find use. Other assay
formats utilizing the compounds of the invention will be apparent
to those of skill in the art.
[0140] In general, to determine the concentration of a target
molecule, such as, for example, a nucleic acid, it is preferable to
first obtain reference data in which constant amounts of probe and
nucleic acid ligand are contacted with varying amounts of target.
The fluorescence emission of each of the reference mixtures is used
to derive a graph or table in which target concentration is
compared to fluorescence emission. For example, a probe that: a)
hybridizes to a target-free nucleic acid ligand; and b) has a
stem-loop architecture with the 5' and 3' termini being the sites
of fluorescent group and BHQ labeling, can be used to obtain such
reference data. Such a probe gives a characteristic emission
profile in which the fluorescence emission decreases as the target
concentration increases in the presence of a constant amount of
probe and nucleic acid ligand. Then, a test mixture with an unknown
amount of target is contacted with the same amount of first nucleic
acid ligand and second probe, and the fluorescence emission is
determined. The value of the fluorescence emission is then compared
with the reference data to obtain the concentration of the target
in the test mixture.
Multiplex Analyses
[0141] In another preferred embodiment, the quenchers of the
invention are utilized as a component of one or more probes used in
a multiplex assay for detecting one or more species in a
mixture.
[0142] Probes that include the BHQs of the invention are
particularly useful in performing multiplex-type analyses and
assays. In a typical multiplex analysis, two or more distinct
species (or regions of one or more species) are detected using two
or more probes, wherein each of the probes is labeled with a
different fluorophore. Preferred species used in multiplex analyses
relying on donor-acceptor energy transfer meet at least two
criteria: the fluorescent species is bright and spectrally
well-resolved; and the energy transfer between the fluorescent
species and the quencher is efficient.
[0143] Thus, in a further embodiment, the invention provides a
mixture comprising at least a first carrier molecule and a second
carrier molecule. The first carrier molecule has covalently bound
thereto a first quencher of excited state energy having a structure
comprising at least three radicals selected from aryl, substituted
aryl, heteroaryl, substituted heteroaryl and combinations thereof.
At least two of the radicals are covalently linked via an exocyclic
diazo bond. The mixture also includes a second carrier molecule.
The second carrier molecule has covalently bound thereto a second
quencher of excited state energy having a structure comprising at
least three radicals selected from aryl, substituted aryl,
heteroaryl, substituted heteroaryl and combinations thereof,
wherein at least two of the radicals are covalently linked via an
exocyclic diazo bond.
[0144] The BHQs of the invention allow for the design of multiplex
assays in which more than one quencher structure is used in the
assay. A number of different multiplex assays using the BHQs of the
invention will be apparent to one of skill in the art. In one
exemplary assay, each of the at least two distinct BHQ quenchers is
used to quench energy derived from one or more identical
fluorophore. Alternatively, an assay can be practiced in which each
distinct BHQ quenches energy derived from a distinct fluorophore to
which the BHQ is "matched." The fluorophores can be bound to the
same molecule as the BHQ or to a different molecule. Moreover,
similar to the BHQs and the fluorophores, the carrier molecules of
use in a particular assay system can be the same or different.
[0145] In addition to the mixtures described above, the present
invention also provides a method for detecting or quantifying a
particular molecular species. The method includes: (a) contacting
the species with a mixture such as that described above; and (b)
detecting a change in a fluorescent property of one or more
component of the mixture, the molecular species or a combination
thereof, thereby detecting or quantifying the molecular
species.
[0146] Because of the ready availability of BHQs of the invention
having different absorbance characteristics, the compounds of the
invention are particularly well suited for use in multiplex
applications. Access to BHQs having a range of absorbance
characteristics allows for the design of donor-acceptor energy
transfer probes in which the acceptor emission properties and the
BHQ absorbance properties are substantially matched, thereby
providing a useful level of spectral overlap (see, for example,
FIG. 7).
[0147] The simultaneous use of two or more probes using
donor-acceptor energy transfer is known in the art. For example,
multiplex assays using nucleic acid probes with different sequence
specificities have been described. Fluorescent probes have been
used to determine whether an individual is homozygous wild-type,
homozygous mutant or heterozygous for a particular mutation. For
example, using one quenched-fluorescein molecular beacon that
recognizes the wild-type sequence and another rhodamine-quenched
molecular beacon that recognizes a mutant allele, it is possible to
genotype individuals for the .beta.-chemokine receptor (Kostrikis
et al. Science 279:1228-1229 (1998)). The presence of only a
fluorescein signal indicates that the individual is wild-type, and
the presence of rhodamine signal only indicates that the individual
is a homozygous mutant. The presence of both rhodamine and
fluorescein signal is diagnostic of a heterozygote. Tyagi et al.
Nature Biotechnology 16: 49-53 (1998)) have described the
simultaneous use of four differently labeled molecular beacons for
allele discrimination, and Lee et al., Bio Techniques 27: 342-349
(1999) have described seven color homogenous detection of six PCR
products.
[0148] The quenchers of the present invention can be used in
multiplex assays designed to detect and/or quantify substantially
any species, including, for example, whole cells, viruses, proteins
(e.g., enzymes, antibodies, receptors), glycoproteins,
lipoproteins, subcellular particles, organisms (e.g., Salmonella),
nucleic acids (e.g., DNA, RNA, and analogues thereof),
polysaccharides, lipopolysaccharides, lipids, fatty acids,
non-biological polymers and small molecules (e.g., toxins, drugs,
pesticides, metabolites, hormones, alkaloids, steroids).
Probes
[0149] The invention provides probes including BHQ moieties
conjugated to, for example, a target species (e.g., receptor,
enzyme, etc.) a ligand for a target species (e.g., nucleic acid,
peptide, etc.), a small molecule (e.g., drug, pesticide, etc.), and
the like. The probes can be used for in vitro and in vivo
applications.
[0150] A particularly unexpected and surprising advantage of the
BHQs is their ability to quench excited state energy from
fluorophores attached to carrier molecules (e.g., nucleic acids)
without the need to design secondary structure forming components
(e.g., hairpins, loops, etc.) into the carrier molecule to bring
the fluorophore and the BHQ into proximity. The energy transfer
pairs of probes presently used in the art typically require the
introduction of some form of secondary structure in order to
function properly, thereby seriously constraining the identity of
species that can be used as carrier molecules. Thus, the probes of
the present invention can be of simple design, can be produced more
inexpensively and used to probe a much greater array of systems in
much less time than current art-recognized probes.
[0151] Yet another unexpected property of the BHQs of the invention
is their robustness under a variety of synthetic conditions used to
attach the BHQs to a carrier molecule. For example, many of the
BHQs of the invention survive the conditions necessary for
automated synthesis of nucleic acids without undergoing any
substantial degree of degradation or alteration. In contrast, many
of the art-recognized quenchers presently in use require the use of
special conditions to assemble the carrier molecule to which they
are attached, or they have to be attached after the completion of
the carrier molecule synthesis. The additional complexity of the
synthesis of a probe increases both the duration of the synthesis
and its cost.
Small Molecule Probes
[0152] The BHQs of the invention can be used as components of small
molecule probes. In a preferred design, a small molecule probe
includes a fluorophore or fluorophore precursor and a BHQ. In an
exemplary embodiment, an agent, such as an enzyme cleaves the BHQ,
the fluorophore or both from the small molecule generating
fluorescence in the system under investigation (see, for example,
Zlokamik et al., Science 279: 84-88 (1998)).
Nucleic Acid Probes
[0153] The dark quenchers of the invention are useful in
conjunction with nucleic-acid probes and they can be used as
components of detection agents in a variety of DNA
amplification/quantification strategies including, for example,
5'-nuclease assay, Strand Displacement Amplification (SDA), Nucleic
Acid Sequence-Based Amplification (NASBA), Rolling Circle
Amplification (RCA), as well as for direct detection of targets in
solution phase or solid phase (e.g., array) assays. Furthermore,
the BHQ-derivatized nucleic acids can be used in probes of
substantially any format, including, for example, format selected
from molecular beacons, Scorpion probes.TM., Sunrise probes.TM.,
conformationally assisted probes, light up probes, Invader
Detection probes, and TaqMan.TM. probes. See, for example,
Cardullo, R., et al., Proc. Natl. Acad. Sci. USA, 85:8790-8794
(1988); Dexter, D. L., J. Chem. Physics, 21:836-850 (1953);
Hochstrasser, R. A., et al., Biophysical Chemistry, 45:133-141
(1992); Selvin, P., Methods in Enzymology, 246:300-334 (1995);
Steinberg, I., Ann. Rev. Biochem., 40:83-114 (1971); Stryer, L.,
Ann. Rev. Biochem., 47:819-846 (1978); Wang, G., et al.,
Tetrahedron Letters, 31:6493-6496 (1990); Wang, Y., etal., Anal.
Chem., 67:1197-1203 (1995); Debouck, C., et al., in supplement to
nature genetics, 21:48-50 (1999); Rehman, F. N., et al., Nucleic
Acids Research, 27:649-655 (1999); Cooper, J. P., et al.,
Biochemistry, 29:9261-9268 (1990); Gibson, E. M., et al., Genome
Methods, 6:995-1001 (1996); Hochstrasser, R. A., et al.,
Biophysical Chemistry, 45:133-141 (1992); Holland, P. M., et al.,
Proc Natl. Acad. Sci USA, 88:7276-7289 (1991); Lee, L. G., et al.,
Nucleic Acids Rsch., 21:3761-3766 (1993); Livak, K. J., et al., PCR
Methods and Applications, Cold Spring Harbor Press (1995); Vamosi,
G., et al., Biophysical Journal, 71:972-994 (1996); Wittwer, C. T.,
et al., Biotechniques, 22:176-181 (1997); Wittwer, C. T., et al.,
Biotechniques, 22:130-38 (1997); Giesendorf, B. A. J., et al.,
Clinical Chemistry, 44:482-486 (1998); Kostrikis, L. G., et al.,
Science, 279:1228-1229 (1998); Matsuo, T., Biochemica et Biophysica
Acta, 1379:178-184 (1998); Piatek, A. S., et al., Nature
Biotechnology, 16:359-363 (1998); Schofield, P., et al., Appl.
Environ. Microbiology, 63:1143-1147 (1997); Tyagi S., et al.,
Nature Biotechnology, 16:49-53 (1998); Tyagi, S., et al., Nature
Biotechnology, 14:303-308 (1996); Nazarenko, I. A., et al., Nucleic
Acids Research, 25:2516-2521 (1997); Uehara, H., et al.,
Biotechniques, 26:552-558 (1999); D. Whitcombe, et al., Nature
Biotechnology, 17:804-807 (1999); Lyamichev, V., et al., Nature
Biotechnology, 17:292 (1999); Daubendiek, et al., Nature
Biotechnology, 15:273-277 (1997); Lizardi, P. M., et al., Nature
Genetics, 19:225-232 (1998); Walker, G., et al., Nucleic Acids
Res., 20:1691-1696 (1992); Walker, G. T., et al., Clinical
Chemistry, 42:9-13 (1996); and Compton, J., Nature, 350:91-92
(1991).
[0154] Thus, in a further aspect, the present invention provides a
method for detecting a nucleic acid target sequence. The method
includes: (a) contacting the target sequence with a detector
nucleic acid; (b) hybridizing the target binding sequence to the
target sequence, thereby altering the conformation of the detector
nucleic acid, causing a change in a fluorescence parameter; and (c)
detecting the change in the fluorescence parameter, thereby
detecting the nucleic acid target sequence.
[0155] In the methods described herein, unless otherwise noted, a
preferred detector nucleic acid includes a single-stranded target
binding sequence. The binding sequence has linked thereto: i) a
fluorophore; and ii) a BHQ of the invention. Moreover, prior to its
hybridization to a complementary sequence, the detector nucleic
acid is preferably in a conformation that allows donor-acceptor
energy transfer between the fluorophore and the BHQ when the
fluorophore is excited. Furthermore, in each of the methods
described in this section, a change in fluorescence is detected as
an indication of the presence of the target sequence. The change in
fluorescence is preferably detected in-real time.
[0156] Presently preferred nucleic acid probes do not require the
carrier molecule to adopt a secondary structure for the probe to
function.
[0157] In this method, and unless otherwise noted, the other
methods described in this section, the detector nucleic acid can
assume substantially any intramolecularly associated secondary
structure, but this structure is preferably a member selected from
hairpins, stem-loop structures, pseudoknots, triple helices and
conformationally assisted structures. Moreover, the
intramolecularly base-paired secondary structure preferably
comprises a portion of the target binding sequence.
[0158] In another aspect, the invention provides a method for
detecting amplification of a target sequence. The method includes
the use of an amplification reaction including the following steps:
(a) hybridizing the target sequence and a detector nucleic acid.
The detector nucleic acid includes a single-stranded target binding
sequence and an intramolecularly associated secondary structure 5'
to the target binding sequence. At least a portion of the detector
sequence forms a single stranded tail which is available for
hybridization to the target sequence; (b) extending the hybridized
detector nucleic acid on the target sequence with a polymerase to
produce a detector nucleic acid extension product and separating
the detector nucleic acid extension product from the target
sequence; (c) hybridizing a primer to the detector nucleic acid
extension product and extending the primer with the polymerase,
thereby linearizing the intramolecularly associated secondary
structure and producing a change in a fluorescence parameter; and
(d) detecting the change in the fluorescence parameter, thereby
detecting the target sequence.
[0159] In yet a further aspect, the invention provides a method of
ascertaining whether a first nucleic acid and a second nucleic acid
hybridize. In this method, the first nucleic acid includes a BHQ
according to the invention. The method includes: (a) contacting the
first nucleic acid with the second nucleic acid; (b) detecting an
alteration in a fluorescent property of a member selected from the
first nucleic acid, the second nucleic acid and a combination
thereof, thereby ascertaining whether the hybridization occurs.
[0160] A probe bearing both a BHQ and a fluorophore can be used or,
alternatively, one or more of the nucleic acids can be singly
labeled with a BHQ or fluorophore. When a nucleic acid singly
labeled with a BHQ is the probe, the interaction between the first
and second nucleic acids can be detected by observing the
interaction between the BHQ and the nucleic acid or, more
preferably, the quenching by the BHQ of the fluorescence of a
fluorophore attached to the second nucleic acid.
[0161] In addition to their general utility in probes designed to
investigate nucleic acid amplification, detection and
quantification, the present dark quenchers can be used in
substantially any nucleic acid probe format now known or later
discovered. For example, the dark quenchers of the invention can be
incorporated into probe motifs, such as Taqman.TM. probes (Held et
al., Genome Res. 6: 986-994 (1996), Holland et al., Proc. Nat.
Acad. Sci. USA 88: 7276-7280 (1991), Lee et al., Nucleic Acids Res.
21: 3761-3766 (1993)), molecular beacons (Tyagi et al., Nature
Biotechnology 14:303-308 (1996), Jayasena et al., U.S. Pat. No.
5,989,823, issued Nov. 23, 1999)) scorpion probes (Whitcomb et al.,
Nature Biotechnology 17: 804-807 (1999)), sunrise probes (Nazarenko
et al., Nucleic Acids Res. 25: 2516-2521 (1997)), conformationally
assisted probes (Cook, R., copending and commonly assigned U.S.
Provisional Application 60/138,376, filed Jun. 9, 1999), peptide
nucleic acid (PNA)-based light up probes (Kubista et al., WO
97/45539, December 1997), double-strand specific DNA dyes (Higuchi
et al, Bio/Technology 10: 413-417 (1992), Wittwer et al,
BioTechniques 22: 130-138 (1997)) and the like. These and other
probe motifs with which the present quenchers can be used are
reviewed in NONISOTOPIC DNA PROBE TECHNIQUES, Academic Press, Inc.
1992.
[0162] The nucleic acids for use in the probes of the invention can
be any suitable size, and are preferably in the range of from about
10 to about 100 nucleotides, more preferably from about 10 to about
80 nucleotides and more preferably still, from about 20 to about 40
nucleotides. The precise sequence and length of a nucleic acid
probe of the invention depends in part on the nature of the target
polynucleotide to which it binds. The binding location and length
may be varied to achieve appropriate annealing and melting
properties for a particular embodiment. Guidance for making such
design choices can be found in many art-recognized references.
[0163] Preferably, the 3'-terminal nucleotide of the nucleic acid
probe is blocked or rendered incapable of extension by a nucleic
acid polymerase. Such blocking is conveniently carried out by the
attachment of a donor or acceptor moiety to the terminal
3'-position of the nucleic acid probe, either directly or by a
linking moiety.
[0164] The nucleic acid can comprise DNA, RNA or chimeric mixtures
or derivatives or modified versions thereof. Both the probe and
target nucleic acid can be present as a single strand, duplex,
triplex, etc. Moreover, the nucleic acid can be modified at the
base moiety, sugar moiety, or phosphate backbone with other groups
such as radioactive labels, minor groove binders, intercalating
agents, donor and/or acceptor moieties and the like.
[0165] For example, the nucleic acid can comprise at least one
modified base moiety which is selected from the group including,
but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil,
5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine,
5-(carboxyhydroxylmethyl)uracil,
5-carboxymethylaminomethyl-2-thiouridine,
5-carboxymethylaminomethyluracil, dihydrouracil,
beta-D-galactosylqueosine, inosine, N.sup.6-isopentenyladenine,
1-methylguanine, 1 -methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N.sup.6-adenine, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil,
5-methoxyuracil, 2-methylthio-N.sup.6-isopentenyladenine,
uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
5-methyluracil, uracil-5-oxyacetic acid methyl ester,
uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil,
3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, nitroindole, and
2,6-diaminopurine.
[0166] In another embodiment, the nucleic acid comprises at least
one modified sugar moiety selected from the group including, but
not limited to, arabinose, 2-fluoroarabinose, xylulose, and
hexose.
[0167] In yet another embodiment, the nucleic acid comprises at
least one modified phosphate backbone selected from the group
including, but not limited to, a peptide nucleic acid hybrid, a
phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a
phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl
phosphotriester, and a formacetal or analog thereof.
[0168] Phosphodiester linked nucleic acids of the invention can be
synthesized by standard methods known in the art, e.g by use of an
automated DNA synthesizer (such as are commercially available from
P.E. Biosystems, etc.) using commercially available amidite
chemistries. Nucleic acids bearing modified phosphodiester linking
groups can be synthesized by methods known in the art. For example,
phosphorothioate nucleic acids may be synthesized by the method of
Stein et al. (Nucl. Acids Res. 16:3209 (1988)), methylphosphonate
nucleic acids can be prepared by use of controlled pore glass
polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A.
85:7448-7451 (1988)). Other methods of synthesizing both
phosphodiester and modified phosphodiester-linked nucleic acids
will be apparent to those of skill in the art.
[0169] Nucleic acid probes of the invention can be synthesized by a
number of approaches, e.g., Ozaki et al., Nucleic Acids Research,
20: 5205-5214 (1992); Agrawal et al., Nucleic Acids Research, 18:
5419-5423 (1990); or the like. The nucleic acid probes of the
invention are conveniently synthesized on an automated DNA
synthesizer, e.g., a P.E. Biosystems, Inc. (Foster City, Calif.)
model 392 or 394 DNA/RNA Synthesizer, using standard chemistries,
such as phosphoramidite chemistry (see, for example, disclosed in
the following references, Beaucage et al., Tetrahedron, 48:
2223-2311 (1992); Molko et al., U.S. Pat. No. 4,980,460; Koster et
al., U.S. Pat. No. 4,725,677; Caruthers et al., U.S. Pat. Nos.
4,415,732; 4,458,066; and 4,973,679. Alternative chemistries
resulting in non-natural backbone groups, such as phosphorothioate,
phosphoramidate, and the like, can also be employed.
[0170] When the nucleic acids are synthesized utilizing an
automated nucleic acid synthesizer, the donor and acceptor moieties
are preferably introduced during automated synthesis.
Alternatively, one or more of these moieties can be introduced
either before or after the automated synthesis procedure has
commenced. For example, donor and/or acceptor groups can be
introduced at the 3'-terminus using a solid support modified with
the desired group(s). Additionally, donor and/or acceptor groups
can be introduced at the 5'-terminus by, for example a derivative
of the group that includes a phosphoramidite. In another exemplary
embodiment, one or more of the donor and/or acceptor groups is
introduced after the automated synthesis is complete.
[0171] In the dual labeled probes, the donor moiety is preferably
separated from the BHQ by at least about 10 nucleotides, and more
preferably by at least about 15 nucleotides. The donor moiety is
preferably attached to either the 3'- or 5'-terminal nucleotides of
the probe. The BHQ moiety is also preferably attached to either the
3'- or 5'-terminal nucleotides of the probe. More preferably, the
donor and acceptor moieties are attached to the 3'- and 5'- or 5'-
and 3'-terminal nucleotides of the probe, respectively, although
internal placement is also useful.
[0172] Once the desired nucleic acid is synthesized, it is
preferably cleaved from the solid support on which it was
synthesized and treated, by methods known in the art, to remove any
protecting groups present (e.g., 60.degree. C., 5 h, concentrated
ammonia). In those embodiments in which a base-sensitive group is
attached to the nucleic acids (e.g., TAMRA), the deprotection will
preferably use milder conditions (e.g., butylamine: water 1:3, 8
hours, 70.degree. C.). Deprotection under these conditions is
facilitated by the use of quick deprotect amidites (e.g.,
dC-acetyl, dG-dmf).
[0173] Following cleavage from the support and deprotection, the
nucleic acid is purified by any method known in the art, including
chromatography, extraction and gel purification. In a preferred
embodiment, the nucleic acid is purified using HPLC. The
concentration and purity of the isolated nucleic acid is preferably
determined by measuring the optical density at 260 nm in a
spectrophotometer.
Peptide Probes
[0174] Peptides, proteins and peptide nucleic acids that are
labeled with a fluorophore and a quencher of the invention can be
used in both in vivo and in vitro enzymatic assays.
[0175] Thus, in another aspect, the present invention provides a
method for determining whether a sample contains an enzyme. The
method comprises: (a) contacting the sample with a peptide
construct; (b) exciting the fluorophore; and (c) determining a
fluorescence property of the sample, wherein the presence of the
enzyme in the sample results in a change in the fluorescence
property.
[0176] Peptide constructs useful in practicing the invention
include those with the following features: i) a fluorophore; ii) a
BHQ of the invention; and iii) a cleavage or assembly recognition
site for the enzyme. Moreover, the peptide construct is preferably
of a length and orientation and in a conformation allowing
donor-acceptor energy transfer between the fluorophore and the BHQ
when the fluorophore is excited.
[0177] When the probe is used to detect an enzyme, such as a
degradative enzyme (e.g., protease), and a degree of donor-acceptor
energy transfer that is lower than an expected amount is observed,
this is generally indicative of the presence of an enzyme. The
degree of donor-acceptor energy transfer in the sample can be
determined, for example, as a function of the amount of
fluorescence from the donor moiety, the amount of fluorescence from
the acceptor moiety, the ratio of the amount of fluorescence from
the donor moiety to the amount of fluorescence from the acceptor
moiety or the excitation state lifetime of the donor moiety.
[0178] The assay also is useful for determining the amount of
enzyme in a sample by determining the degree of donor-acceptor
energy transfer at a first and second time after contact between
the enzyme and the tandem construct, and determining the difference
in the degree of donor-acceptor energy transfer. The difference in
the degree of donor-acceptor energy transfer reflects the amount of
enzyme in the sample.
[0179] The assay methods also can also be used to determine whether
a compound alters the activity of an enzyme, i.e., screening
assays. Thus, in a further aspect, the invention provides methods
of determining the amount of activity of an enzyme in a sample from
an organism. The method includes: (a) contacting a sample
comprising the enzyme and the compound with a peptide construct
comprising (b) exciting the fluorophore; and (c) determining a
fluorescence property of the sample, wherein the activity of the
enzyme in the sample results in a change in the fluorescence
property. Peptide constructs useful in this aspect of the invention
are substantially similar to those described immediately above.
[0180] In a preferred embodiment, the amount of enzyme activity in
the sample is determined as a function of the degree of
donor-acceptor energy transfer in the sample and the amount of
activity in the sample is compared with a standard activity for the
same amount of the enzyme. A difference between the amount of
enzyme activity in the sample and the standard activity indicates
that the compound alters the activity of the enzyme.
[0181] Representative enzymes with which the present invention can
be practiced include, for example, trypsin, enterokinase, HIV-1
protease, prohormone convertase, interleukin-1b-converting enzyme,
adenovirus endopeptidase, cytomegalovirus assemblin,
leishmanolysin, .beta.-secretase for amyloid precursor protein,
thrombin, renin, angiotensin-converting enzyme, cathepsin-D and a
kininogenase, and proteases in general.
[0182] Proteases play essential roles in many disease processes
such as Alzheimer's, hypertension, inflammation, apoptosis, and
AIDS. Compounds that block or enhance their activity have potential
as therapeutic agents. Because the normal substrates of peptidases
are linear peptides and because established procedures exist for
making non-peptidic analogs, compounds that affect the activity of
proteases are natural subjects of combinatorial chemistry.
Screening compounds produced by combinatorial chemistry requires
convenient enzymatic assays.
[0183] The most convenient assays for proteases are based on
donor-acceptor energy transfer from a donor fluorophore to a
quencher placed at opposite ends of a short peptide chain
containing the potential cleavage site (see, Knight C. G., Methods
in Enzymol. 248:18-34 (1995)). Proteolysis separates the
fluorophore and quencher, resulting in increased intensity in the
emission of the donor fluorophore. Existing protease assays use
short peptide substrates incorporating unnatural chromophoric amino
acids, assembled by solid phase peptide synthesis.
[0184] Assays of the invention are also useful for determining and
characterizing substrate cleavage sequences of proteases or for
identifying proteases, such as orphan proteases. In one embodiment
the method involves the replacement of a defined linker moiety
amino acid sequence with one that contains a randomized selection
of amino acids. A library of fluorescent BHQ-bearing probes,
wherein the fluorophore and the BHQ are linked by a randomized
peptide linker moiety can be generated using recombinant
engineering techniques or synthetic chemistry techniques. Screening
the members of the library can be accomplished by measuring a
signal related to cleavage, such as donor-acceptor energy transfer,
after contacting the cleavage enzyme with each of the library
members of the tandem fluorescent peptide construct. A degree of
donor-acceptor energy transfer that is lower than an expected
amount indicates the presence of a linker sequence that is cleaved
by the enzyme. The degree of donor-acceptor energy transfer in the
sample can be determined, for example, as a function of the amount
of fluorescence from the donor moiety, the amount of fluorescence
from the acceptor donor moiety, or the ratio of the amount of
fluorescence from the donor moiety to the amount of fluorescence
from the acceptor moiety or the excitation state lifetime of the
donor moiety.
[0185] In the tandem constructs of the invention, the donor and
acceptor moieties are connected through a linker moiety. The linker
moiety, preferably, includes a peptide moiety, but can be or can
include another organic molecular moiety, as well. In a preferred
embodiment, the linker moiety includes a cleavage recognition site
specific for an enzyme or other cleavage agent of interest. A
cleavage site in the linker moiety is useful because when a tandem
construct is mixed with the cleavage agent, the linker is a
substrate for cleavage by the cleavage agent. Rupture of the linker
moiety results in separation of the fluorophore and the quencher of
the invention. The separation is measurable as a change in
donor-acceptor energy transfer. Alternatively, peptide assembly can
be detected by an increase in donor-acceptor energy transfer
between a peptide fragment bearing a BHQ and a peptide fragment
bearing a donor moiety.
[0186] When the cleavage agent of interest is a protease, the
linker generally includes a peptide containing a cleavage
recognition sequence for the protease. A cleavage recognition
sequence for a protease is a specific amino acid sequence
recognized by the protease during proteolytic cleavage. Many
protease cleavage sites are known in the art, and these and other
cleavage sites can be included in the linker moiety. See, e.g.,
Matayoshi et al. Science 247: 954 (1990); Dunn et al. Meth.
Enzymol. 241: 254 (1994); Seidah et al. Meth. Enzymol. 244: 175
(1994); Thomberry, Meth. Enzymol. 244: 615 (1994); Weber et al.
Meth. Enzymol. 244: 595 (1994); Smith et al. Meth. Enzymol. 244:
412 (1994); Bouvier et al. Meth. Enzymol. 248: 614 (1995), Hardy et
al., in AMYLOID PROTEIN PRECURSOR IN DEVELOPMENT, AGING, AND
ALZHEIMER'S DISEASE, ed. Masters et al. pp. 190-198 (1994).
Solid Support Immobilized BHO Analogues
[0187] The BHQs of the invention can be immobilized on
substantially any polymer, biomolecule, and solid or semi-solid
material having any useful configuration. Moreover, any conjugate
comprising one or more BHQs can be similarly immobilized. When the
support is a solid or semi-solid, examples of preferred types of
supports for immobilization of the nucleic acid probe include, but
are not limited to, controlled pore glass, glass plates,
polystyrene, avidin coated polystyrene beads, cellulose, nylon,
acrylamide gel and activated dextran. These solid supports are
preferred because of their chemical stability, ease of
finctionalization and well-defined surface area. Solid supports
such as, controlled pore glass (CPG, 500 .ANG., 1000 .ANG.) and
non-swelling high cross-linked polystyrene (1000 .ANG.) are
particularly preferred.
[0188] According to the present invention, the surface of a solid
support is functionalized with a quencher of the invention or a
species including a quencher of the invention. For clarity of
illustration, the following discussion focuses on attaching a
reactive BHQ to a solid support. The following discussion is also
broadly relevant to attaching a species that includes within its
structure a reactive BHQ to a solid support, and the attachment of
such species and reactive BHQ analogues to other molecules and
structures.
[0189] The BHQs are preferably attached to a solid support by
forming a bond between a reactive group on the BHQ and a reactive
group on the surface of the solid support or a linker attached to
the solid support, thereby derivatizing the solid support with one
or more BHQ analogues. The bond between the solid support and the
BHQ is preferably a covalent bond, although ionic, dative and other
such bonds are useful as well. Reactive groups which can be used in
practicing the present invention are discussed in detail above and
include, for example, amines, hydroxyl groups, carboxylic acids,
carboxylic acid derivatives, alkenes, sulfhydryls, siloxanes,
etc.
[0190] A large number of solid supports appropriate for practicing
the present 20 invention are available commercially and include,
for example, peptide synthesis resins, both with and without
attached amino acids and/or peptides (e.g., alkoxybenzyl alcohol
resin, aminomethyl resin, aminopolystyrene resin, benzhydrylamine
resin, etc. (Bachem)), functionalized controlled pore glass
(BioSearch Technologies, Inc.), ion exchange media (Aldrich),
functionalized membranes (e.g., --COOH membranes; Asahi Chemical
Co., Asahi Glass Co., and Tokuyama Soda Co.), and the like.
[0191] Moreover, for applications in which an appropriate solid
support is not commercially available, a wide variety of reaction
types are available for the functionalization of a solid support
surface. For example, supports constructed of a plastic such as
polypropylene, can be surface derivatized by chromic acid
oxidation, and subsequently converted to hydroxylated or
aminomethylated surfaces. The functionalized support is then
reacted with a BHQ of complementary reactivity, such as a BHQ
active ester, acid chloride or sulfonate ester, for example.
Supports made from highly crosslinked divinylbenzene can be surface
derivatized by chloromethylation and subsequent finctional group
manipulation. Additionally, functionalized substrates can be made
from etched, reduced polytetrafluoroethylene.
[0192] When the support is constructed of a siliceous material such
as glass, the surface can be derivatized by reacting the surface
Si--OH, SiO--H, and/or Si--Si groups with a functionalizing
reagent.
[0193] In a preferred embodiment, wherein the substrates are made
from glass, the covalent bonding of the reactive group to the glass
surface is achieved by conversion of groups on the substrate's
surface by a silicon-modifying reagent such as:
(R.sup.aO).sub.3--Si--R.sup.b--X.sup.a (VII) where R.sup.a is an
alkyl group, such as methyl or ethyl, R.sup.b is a linking group
between silicon and X.sup.a, and X.sup.a is a reactive group or a
protected reactive group. Silane derivatives having halogens or
other leaving groups beside the displayed alkoxy groups are also
useful in the present invention.
[0194] In another preferred embodiment, the reagent used to
functionalize the solid support provides for more than one reactive
group per each reagent molecule. Using reagents, such as the
compound below, each reactive site on the substrate surface is, in
essence, "amplified" to two or more functional groups:
(R.sup.aO).sub.3--Si--R.sup.b--(X.sup.a).sub.n (VIII) where R.sup.a
is an alkyl group (e.g.,methyl, ethyl), R.sup.b is a linking group
between silicon and X.sup.a, X.sup.a is a reactive group or a
protected reactive group and n is an integer between 2 and 50, and
more preferably between 2 and 20. The amplification of a BHQ by its
attachment to a silicon-containing substrate is intended to be
exemplary of the general concept of BHQ amplification. This
amplification strategy is equally applicable to other aspects of
the invention in which a BHQ analogue is attached to another
molecule or solid support.
[0195] A number of siloxane functionalizing reagents can be used,
for example: [0196] 1. Hydroxyalkyl siloxanes (Silylate surface,
functionalize with diborane, and H.sub.2O.sub.2 to oxidize to the
alcohol) [0197] a. allyl trichlorosilane .fwdarw..fwdarw.
3-hydroxypropyl [0198] b. 7-oct-1-enyl trichlorchlorosilane
.fwdarw..fwdarw. 8-hydroxyoctyl [0199] 2. Diol (dihydroxyalkyl)
siloxanes (silylate surface and hydrolyze to diol)a. (glycidyl
trimethoxysilane .fwdarw..fwdarw. (2,3-dihydroxypropyloxy)propyl
[0200] 3. Aminoalkyl siloxanes (amines requiring no intermediate
functionalizing step) [0201] a. 3-aminopropyl trimethoxysilane
.fwdarw. aminopropyl [0202] 4. Dimeric secondary aminoalkyl
siloxanes [0203] a. bis (3-trimethoxysilylpropyl)amine .fwdarw.
bis(silyloxylpropyl)amine.
[0204] It will be apparent to those of skill in the art that an
array of similarly useful functionalizing chemistries is available
when support components other than siloxanes are used. Thus, for
example alkyl thiols, functionalized as discussed above in the
context of siloxane-modifying reagents, can be attached to metal
films and subsequently reacted with a BHQ to produce the
immobilized compound of the invention.
[0205] R groups of use for R.sup.b in the above described
embodiments of the present invention include, but are not limited
to, alkyl, substituted alkyl, aryl, arylalkyl, substituted aryl,
substituted arylalkyl, acyl, halogen, hydroxy, amino, alkylamino,
acylamino, alkoxy, acyloxy, aryloxy, aryloxyalkyl, mercapto,
saturated cyclic hydrocarbon, unsaturated cyclic hydrocarbon,
heteroaryl, heteroarylalkyl, substituted heteroaryl, substituted
heteroarylalkyl, heterocyclic, substituted heterocyclic and
heterocyclicalkyl groups and combinations thereof.
Nucleic Acid Capture Probes
[0206] In one embodiment, an immobilized nucleic acid comprising a
BHQ is used as a capture probe. The nucleic acid probe can be
attached directly to a solid support, for example by attachment of
the 3'- or 5'-terminal nucleotide of the probe to the solid
support. More preferably, however, the probe is attached to the
solid support by a linker (i.e., spacer arm, supra). The linker
serves to distance the probe from the solid support. The linker is
most preferably from about 5 to about 30 atoms in length, more
preferably from about 10 to about 50 atoms in length.
[0207] In yet another preferred embodiment, the solid support is
also used as the synthesis support in preparing the probe. The
length and chemical stability of the linker between the solid
support and the first 3'-unit of nucleic acid play an important
role in efficient synthesis and hybridization of support bound
nucleic acids. The linker arm should be sufficiently long so that a
high yield (>97%) can be achieved during automated synthesis.
The required length of the linker will depend on the particular
solid support used. For example, a six atom linker is generally
sufficient to achieve a >97% yield during automated synthesis of
nucleic acids when high cross-linked polystyrene is used as the
solid support. The linker arm is preferably at least 20 atoms long
in order to attain a high yield (>97%) during automated
synthesis when CPG is used as the solid support.
[0208] Hybridization of a probe immobilized on a solid support
generally requires that the probe be separated from the solid
support by at least 30 atoms, more preferably at least 50 atoms. In
order to achieve this separation, the linker generally includes a
spacer positioned between the linker and the 3'-terminus. For
nucleic acid synthesis, the linker arm is usually attached to the
3'-OH of the 3'-terminus by an ester linkage which can be cleaved
with basic reagents to free the nucleic acid from the solid
support.
[0209] A wide variety of linkers are known in the art, which may be
used to attach the nucleic acid probe to the solid support. The
linker may be formed of any compound, which does not significantly
interfere with the hybridization of the target sequence to the
probe attached to the solid support. The linker may be formed of,
for example, a homopolymeric nucleic acid, which can be readily
added on to the linker by automated synthesis. Alternatively,
polymers such as functionalized polyethylene glycol can be used as
the linker. Such polymers are presently preferred over
homopolymeric nucleic acids because they do not significantly
interfere with the hybridization of probe to the target nucleic
acid. Polyethylene glycol is particularly preferred because it is
commercially available, soluble in both organic and aqueous media,
easy to functionalize, and completely stable under nucleic acid
synthesis and post-synthesis conditions.
[0210] The linkages between the solid support, the linker and the
probe are preferably not cleaved during synthesis or removal of
base protecting groups under basic conditions at high temperature.
These linkages can, however, be selected from groups that are
cleavable under a variety of conditions. Examples of presently
preferred linkages include carbamate, ester and amide linkages.
Acrylamide-Immobilized Probes
[0211] In another preferred embodiment, a species is within a
matrix, such as an acrylamide matrix and the species bears a BHQ,
or the presence of the immobilized species is ascertained using a
probe bearing a BHQ. In a preferred embodiment, the immobilization
is accomplished in conjunction with the "acrydite" process invented
and commercialized by Mosaic Technologies (Cambridge, Mass., see,
Rehman et al., Nucleic Acids Research, 27: 649-655 (1999)). The
acrydite method allows immobilization of alkene labeled capture
probes within a polymerized polyacrylamide network. When target
mixes are run past the immobilized probe band under electrophoresis
conditions, the target nucleic acid is captured substantially
quantitatively. However, detection of this event currently requires
a second probe. In one embodiment, probes bearing a BHQ, and/or a
fluorophore, are immobilized in an acrylamide matrix and
subsequently contacted with the target mix. By using fluorescent
probes as capture probes, signals from target mixes can be directly
detected in real time.
Microarrays
[0212] The present invention also provides microarrays including
immobilized BHQs and compounds (e.g., peptides, nucleic acids,
bioactive agents, etc.) functionalized with BHQs. Moreover, the
invention provides methods of interrogating microarrays using
probes that are functionalized with BHQs. The immobilized species
and the probes are selected from substantially any type of
molecule, including, but not limited to, small molecules, peptides,
enzymes nucleic acids and the like.
[0213] Nucleic acid microarrays consisting of a multitude of
immobilized nucleic acids are revolutionary tools for the
generation of genomic information, see, Debouck et al., in
supplement to Nature Genetics, 21:48-50 (1999)** . The discussion
that follows focuses on the use of BHQs in conjunction with nucleic
acid microarrays. This focus is intended to be illustrative and
does not limit the scope of materials with which this aspect of the
present invention can be practiced.
[0214] In another preferred embodiment, the compounds of the
present invention are utilized in a microarray format. The BHQs, or
species bearing BHQs can themselves be components of a microarray
or, alternatively they can be utilized as a tool to screen
components of a microarray.
[0215] Thus, in a preferred embodiment, the present invention
provides a method of screening a microarray. The method includes
contacting the members of the microarray with, for example, a
BHQ-bearing probe and interrogating the microarray for regions of
fluorescence. In an exemplary embodiment, fluorescent regions are
indicative of the presence of an interaction between the
BHQ-bearing probe and a microarray component. In another version of
this method, the microarray is interrogated for regions in which
fluorescence is quenched by the BHQ, again indicating the presence
of an interaction between the BHQ-bearing probe and a component of
the microarray.
[0216] In another preferred embodiment, the array comprises
immobilized BHQ-bearing donor-acceptor energy transfer probes as
the interrogating species. In this embodiment, the probe "turns on"
when hybridized to its target. Such arrays are easily prepared and
read, and can be designed to give quantitative data. Arrays
comprising BHQ-bearing probes are valuable tools for expression
analysis and clinical genomic screening.
[0217] In another preferred embodiment, the immobilized BHQ-bearing
probe is not a donor-acceptor energy transfer probe. A microarray
based on such as format can be used to probe for the presence of
interactions between an analyte and the immobilized probe by, for
example, observing the quenching of analyte fluorescence upon
interaction between the probe and analyte.
[0218] In a further preferred embodiment, the microarrays comprise
n regions that comprise identical or different species (e.g.,
nucleic acid sequences, bioactive agents). For example, the
microarray can comprise a mixture of n regions comprising groups of
identical species. In a preferred embodiment, n is a number from 2
to 100, more preferably, from 10 to 1,000, and more preferably from
100 to 10,000. In a still further preferred embodiment, the n
regions are patterned on a substrate as n distinct locations in a
manner that allows the identity of each of the n locations to be
ascertained.
[0219] In yet another preferred embodiment, the invention also
provides a method for preparing a microarray of n BHQ-bearing
probes. The method includes attaching BHQ-bearing probes to
selected regions of a substrate. A variety of methods are currently
available for making arrays of biological macromolecules, such as
arrays nucleic acid molecules. The following discussion focuses on
the assembly of a microarray of BHQ-bearing probes, this focus is
for reasons of brevity and is intended to be illustrative and not
limiting.
[0220] One method for making ordered arrays of BHQ-bearing probes
on a substrate is a "dot blot" approach. In this method, a vacuum
manifold transfers a plurality, e.g., 96, aqueous samples of probes
from 3 millimeter diameter wells to a substrate. The probe is
immobilized on the porous membrane by baking the membrane or
exposing it to UV radiation. A common variant of this procedure is
a "slot-blot" method in which the wells have highly-elongated oval
shapes.
[0221] Another technique employed for making ordered arrays of
probes uses an array of pins dipped into the wells, e.g., the 96
wells of a microtiter plate, for transferring an array of samples
to a substrate, such as a porous membrane. One array includes pins
that are designed to spot a membrane in a staggered fashion, for
creating an array of 9216 spots in a 22.times.22 cm area. See,
Lehrach, et al., HYBRIDIZATION FINGERPRINTING IN GENOME MAPPING AND
SEQUENCING, GENOME ANALYSIS, Vol. 1, Davies et al, Eds., Cold
Springs Harbor Press, pp. 39-81 (1990).
[0222] An alternate method of creating ordered arrays of probes is
analogous to that described by Pirrung et al. (U.S. Pat. No.
5,143,854, issued 1992), and also by Fodor et al., (Science, 251:
767-773 (1991)). This method involves synthesizing different probes
at different discrete regions of a particle or other substrate.
This method is preferably used with relatively short probe
molecules, e.g., less than 20 bases. A related method has been
described by Southern et al. (Genomics, 13: 1008-1017 (1992)).
[0223] Khrapko, et al., DNA Sequence, 1: 375-388 (1991) describes a
method of making an nucleic acid matrix by spotting DNA onto a thin
layer of polyacrylamide. The spotting is done manually with a
micropipette.
[0224] The substrate can also be patterned using techniques such as
photolithography (Kleinfield et al., J. Neurosci. 8:4098-120
(1998)), photoetching, chemical etching and microcontact printing
(Kumar et al., Langmuir 10: 1498-511 (1994)). Other techniques for
forming patterns on a substrate will be readily apparent to those
of skill in the art.
[0225] The size and complexity of the pattern on the substrate is
limited only by the resolution of the technique utilized and the
purpose for which the pattern is intended. For example, using
microcontact printing, features as small as 200 nm are layered onto
a substrate. See, Xia, Y., J. Am. Chem. Soc. 117:3274-75 (1995).
Similarly, using photolithography, patterns with features as small
as 1 .mu.m are produced. See, Hickman et al., J. Vac. Sci. Technol.
12:607-16 (1994). Patterns which are useful in the present
invention include those which include features such as wells,
enclosures, partitions, recesses, inlets, outlets, channels,
troughs, diffraction gratings and the like.
[0226] In a presently preferred embodiment, the patterning is used
to produce a substrate having a plurality of adjacent wells,
indentations or holes to contain the probes. In general, each of
these substrate features is isolated from the other wells by a
raised wall or partition and the wells do not readily fluidically
communicate. Thus, a particle, reagent or other substance, placed
in a particular well remains substantially confined to that well.
In another preferred embodiment, the patterning allows the creation
of channels through the device whereby an analyte or other
substance can enter and/or exit the device.
[0227] In another embodiment, the probes are immobilized by
"printing" them directly onto a substrate or, alternatively, a
"lift off" technique can be utilized. In the lift off technique, a
patterned resist is laid onto the substrate, and a probe is laid
down in those areas not covered by the resist and the resist is
subsequently removed. Resists appropriate for use with the
substrates of the present invention are known to those of skill in
the art. See, for example, Kleinfield et al., J. Neurosci.
8:4098-120 (1998). Following removal of the photoresist, a second
probe, having a structure different from the first probe can be
bonded to the substrate on those areas initially covered by the
resist. Using this technique, substrates with patterns of probes
having different characteristics can be produced. Similar substrate
configurations are accessible through microprinting a layer with
the desired characteristics directly onto the substrate. See,
Mrkish et al. Ann. Rev. Biophys. Biomol. Struct. 25:55-78
(1996).
Spacer Groups
[0228] As used herein, the term "spacer group," refers to
constituents of BHQ-bearing probes. The spacer group links donor
and/or acceptor moieties and other groups to the nucleic acid,
peptide or other component of the probe. The spacer groups can be
hydrophilic (e.g., tetraethylene glycol, hexaethylene glycol,
polyethylene glycol) or they can be hydrophobic (e.g., hexane,
decane, etc.).
[0229] In a preferred embodiment, using solid supports the
immobilized construct includes a spacer between the solid support
reactive group and the BHQ analogue. The linker is preferably
selected from C.sub.6-C.sub.30 alkyl groups, C.sub.6-C.sub.30
substituted alkyl groups, polyols, polyethers (e.g.,
poly(ethyleneglycol)), polyamines, polyamino acids, polysaccharides
and combinations thereof.
[0230] In certain embodiments, it is advantageous to have the donor
and/or acceptor of the probe attached to another polymeric
component by a group that provides flexibility and distance from
the polymeric component. Using such spacer groups, the properties
of the donor and/or acceptor adjacent to another probe component is
modulated. Properties that are usefully controlled include, for
example, hydrophobicity, hydrophilicity, surface-activity, the
distance of the donor and/or BHQ moiety from the other probe
components (e.g., carrier molecule) and the distance of the donor
from the BHQ.
[0231] In an exemplary embodiment, the spacer serves to distance
the BHQ from a nucleic acid. Spacers with this characteristic have
several uses. For example, a BHQ held too closely to the nucleic
acid may not interact with the donor group, or it may interact with
too low of an affinity. When a BHQ is itself sterically demanding,
the interaction leading to quenching can be undesirably weakened,
or it may not occur at all, due to a sterically-induced hindering
of the approach of the two components.
[0232] When the construct comprising the BHQ is immobilized by
attachment to, for example, a solid support, the construct can also
include a spacer moiety between the reactive group of the solid
support and the BHQ analogue, or other probe component bound to the
solid support.
[0233] In yet a further embodiment, a spacer group used in the
probes of the invention is provided with a group that can be
cleaved to release a bound moiety, such as, for example, a BHQ,
fluorophore, minor groove binder, intercalating moiety, and the
like from the polymeric component. Many cleaveable groups are known
in the art. See, for example, Jung et al., Biochem. Biophys. Acta,
761: 152-162 (1983); Joshi et al., J. Biol. Chem., 265: 14518-14525
(1990); Zarling et al., J. Immunol., 124: 913-920 (1980); Bouizar
et al., Eur. J. Biochem., 155: 141-147 (1986); Park et al., J.
Biol. Chem., 261: 205-210 (1986); Browning et al., J. Immunol.,
143: 1859-1867 (1989). Moreover a broad range of cleavable,
bifunctional (both homo- and hetero-bifunctional) spacer arms are
commercially available from suppliers such as Pierce.
[0234] An exemplary embodiment utilizing spacer groups is set forth
in Formulae VII and VIII, above. In these formulae, R.sup.b is
either stable or it can be cleaved by chemical or photochemical
reactions. For example, R.sup.b groups comprising ester or
disulfide bonds can be cleaved by hydrolysis and reduction,
respectively. Also within the scope of the present invention is the
use of R.sup.b groups which are cleaved by light such as, for
example, nitrobenzyl derivatives, phenacyl groups, benzoin esters,
etc. Other such cleaveable groups are well-known to those of skill
in the art.
Kits
[0235] In another aspect, the present invention provides kits
containing one or more of the BHQs or BHQ-bearing compositions of
the invention. In one embodiment, a kit will include a reactive BHQ
derivative and directions for attaching this derivative to another
molecule. In another embodiment, the kit includes a BHQ-labeled
nucleic acid that optionally is also labeled with a fluorophore and
directions for using this nucleic acid in one or more assay
formats. Other formats for kits will be apparent to those of skill
in the art and are within the scope of the present invention.
[0236] The materials and methods of the present invention are
further illustrated by the examples which follow. These examples
are offered to illustrate, but not to limit the claimed
invention.
EXAMPLES
[0237] The following Examples illustrate the synthesis and
characterization of exemplary species of the invention.
[0238] Example 1 sets for the synthesis of the quencher BH1 and its
conversion into a controlled pore glass conjugate. Examples 2 and
3, provide similar details regarding the quenchers BH2 and BH3.
[0239] Example 4 sets forth the incorporation of exemplary
quenchers of the invention into nucleic acid-based donor-acceptor
energy transfer probes. The quenching efficiency of the BHQs in the
probes is assessed and compared to that of the art-recognized dark
quencher DABCYL.
Example 1
[0240] This Example sets forth the synthesis and characterization
of BH1 and derivatives thereof.
1.1 Synthesis of
4-methyl-2-nitrobenzylazo-2'-methyl-5'-nitrobenzylazo-4''-N,N-di(2-hydrox-
yethyl) azobenzene, (BH1 diol), 6
[0241] To a rapidly stirred suspension of 25 g (60 mmol) Fast
Corinth V salt (Aldrich 22,736-5) in 400 mL of chilled water (ice
bath) was added 50 g (276 mmol) N-phenyldiethanolamine dissolved in
400 mL methanol and 300 mL sat'd NaHCO.sub.3 over 20 min. The
mixture changed color from yellow to deep red during the course of
the addition. The mixture was chilled for an additional 1 hr after
addition, then filtered through a medium glass frit. The dark red
solid was washed with 300 ml of ice cold water and air dried for 3
days. The yield of 6 was 27 g, (91%). TLC rf 0.15 (Silica plate, 5%
MeOH in CH.sub.2Cl.sub.2). MALDI M/e 493.11 (Calc'd 492.5). .sup.1H
NMR (CDCl.sub.3, .delta.) 7.9 (d, 2H), 7.65 (m, 2H), 7.6 (s, 1H),
7.45(d, 1H), 7.4(s, 1H), 6.8(d, 2H), 4.0(s, 3H), 3.95(t, 2H),
3.85(t, 2H), 3.7(t, 2H), 3.6(t, 2H), 2.7(s, 3H), 2.5(s, 3H).
1.2 Synthesis of
4-methyl-2-nitrobenzylazo-2'-methyl-5'-nitrobenzylazo-4''-N,N-(2-hydroxye-
thyl)-(2-O-(4,4'dimethoxytrityl)ethylazobenzene (DMT-BH1), 7
[0242] A solution of 25 g (50 mmol) 6 in 400 mL of dry pyridine was
stripped to dryness, and 7 g (21 mmol) of DMT-chloride was added in
300 mL of dry pyridine. The solution sat for 3 days at rt, then was
stripped to a tar. The black residue was dissolved in 600 mL ethyl
acetate, and washed with 300 mL of 1 N aqueous citric acid,
followed by a 300 mL sat'd aqueous NaHCO.sub.3 wash. The organic
layer was dried over MgSO.sub.4 and stripped to a tar. The residue
was loaded onto a 55 by 8 cm chromatography column of neutral
alumina, 7% by weight water, and eluted first with a mobile phase
of 0.5% MeOH, 0.5% pyridine in CH.sub.2Cl.sub.2. After 1 L of
solvent eluted, a gradient to 2% MeOH was run over 4 L. Fractions
containing pure 7 (0.42 rf, silica plate, 2% MeOH, 2% pyridine in
CH.sub.2Cl.sub.2) were pooled and evaporated. The yield was 2.8 g
(17% yield) of 2 as a dark foam. MALDI M/e 793.88 (Calc'd 794.5).
.sup.1H NMR (CDCl.sub.3, .delta.) 7.85 (d, 2H), 7.7 (m, 4H), 7.6
(s, 1H), 7.45(d, 1H), 7.4-7.1 (m, 10H), 6.8(m, 6H), 4.0(s, 3H),
3.85(m, 2H), 3.75 (s, 6H), 3.7(m, 2H), 3.5-3.3(m, 4H), 2.7(s, 3H),
2.5(s, 3H).
1.3 Synthesis of
4-methyl-2-nitrobenzylazo-2'-methyl-5'-nitrobenzylazo-4''-N,N-(2-O-(N',N'-
-diisopropyl-2-cyanoethylphosphite)ethyl)-(2-O-4,4'dimethoxytrityl)-ethyl)-
azobenzene, (DMT-BH1 amidite), 8
[0243] A solution of 2.8 g (3.5 mmol) of 7 in 50 mL of dry pyridine
was evaporated to dryness and high vacuum applied for several hrs.
A solution of 1.5 g (5 mmol) of
N,N,N',N'-tetraisopropyl-2-cyanoethylphosphane and 60 mg of
tetrazole were mixed in 20 mL of dry acetonitrile and added to the
flask containing the dried 7. After 2 hrs, the solvent was
stripped, and the residue was dissolved in 200 mL of EtOAc. The
organic layer was washed with 100 mL sat'd aqueous NaHCO.sub.3 and
dried over MgSO.sub.4. The solvent was evaporated, and the residue
applied to a 25 by 3 cm chromatography column of neutral alumina,
7% by weight water, and eluted with a mobile phase of 75% Pet.
ether, 23% EtOAc, 2% pyridine. Fractions containing pure 8 (0.67
rf, pre-run silica plate, 50% Pet. ether, 48% EtOAc, 2% pyridine)
were pooled and evaporated. The yield was 1 g (20% yield) of 8 as a
dark foam. MALDI M/e 995.5 (Calc'd 994.5).
1.4 Synthesis of BH1-CPG, 9
[0244] 11 g DMT-2,2'-sulfonyldiethanol-succinyl controlled pore
glass, 500 .ANG., Biosearch part # BGS-5000, was washed three times
with 3% dichloroacetic acid to effect removal of the DMT group. The
CPG was washed well with three 50 mL portions of CH.sub.2Cl.sub.2,
followed by one 50 mL wash with dry pyridine. The CPG was added to
the flask containing 1 g of 8. 25 mL of dry pyridine was added, and
the solvent was removed by rotary evaporation, followed by high
vacuum for 3 hrs. The dried CPG and amidite were treated with a
solution of 1 g S-ethyl tetrazole in 20 mL of dry acetonitrile for
20 min. The CPG was washed in a sintered glass funnel twice with 50
mL of acetonitrile, then 50 mL of 0.02 M iodine in 90% THF, 8%
water and 2% pyridine were added. After 5 min, the iodine solution
was washed out of the CPG with three 50 mL portions of
acetonitrile, then a capping solution of 10% Ac.sub.2O, 10%
N-methylimidazole and 10% pyridine in THF was added. After 20 min,
the solution was washed out of the CPG with three 50 mL portions of
acetonitrile, followed by three 50 mL portions of CH.sub.2Cl.sub.2.
The material was dried overnight under high vacuum. DMT loading
determination on the dried material was 16 .mu.M/g.
Example 2
[0245] This Example sets forth the synthesis and characterization
of BH2 and derivatives thereof.
2.1 Synthesis of
4-nitrobenzylazo-2',5'-dimethoxybenzylazo-4''-N,N-di(2-hydroxyethyl)azobe-
nzene, (BH2 diol), 10
[0246] To a rapidly stirred suspension of 25 g (60 mmol) Fast Black
K salt (Aldrich 20,151-0) in 400 mL of chilled water (ice bath) was
added 50 g (276 mmol) N-phenyldiethanolamine dissolved in 400 mL
methanol and 300 mL sat'd NaHCO.sub.3 over 20 min. The mixture
changed color from brown to deep blue during the course of the
addition. The mixture was chilled for an additional 1 hr after
addition, then filtered through a medium glass frit. The dark blue
solid was washed with 300 ml of ice cold water and air dried for 3
days. The yield of 10 was 22 g, (74%). TLC rf 0.2 (Silica plate, 5%
MeOH in CH.sub.2Cl.sub.2). MALDI M/e 493.13 (Calc'd 494.4). .sup.1H
NMR (CDCl.sub.3, .delta.) 8.3 (d, 2H), 8.0(d, 2H), 7.85(d, 2H),
7.4(d, 2H), 6.7(m, 2H), 4.1(s, 3H), 3.95(s, 3H), 3.9(t, 2H), 3.8(t,
2H), 3.7(t, 2H), 3.5(t, 3H).
2.2 Synthesis of
4-nitrobenzylazo-2',5'-dimethoxybenzylazo-4''-N,N-(2-hydroxy-ethyl)-(2-O--
(4,4'dimethoxytrityl)ethylazobenzene1, (DMT-BH2), 11
[0247] A solution of 22 g (44 mmol) 10 in 400 mL of dry pyridine
was stripped to dryness, and 7 g (21 mmol) of DMT-chloride was
added in 300 mL of dry pyridine. The solution sat for 3 days at rt,
then was stripped to a tar. The black residue was dissolved in 600
mL ethyl acetate, and washed with 300 mL of 1 N aqueous citric
acid, followed by a 300 mL sat'd aqueous NaHCO.sub.3 wash. The
organic layer was dried over MgSO.sub.4 and stripped to a tar. The
residue was loaded onto a 55 by 8 cm chromatography column of
neutral alumina, 7% by weight water, and eluted first with a mobile
phase of 0.5% MeOH, 0.5% pyridine in CH.sub.2Cl.sub.2. After 1 L of
solvent eluted, a gradient to 2% MeOH was run over 4 L. Fractions
containing pure 11 (0.4 rf, silica plate, 2% MeOH, 2% pyridine in
CH.sub.2Cl.sub.2) were pooled and evaporated. The yield was 2.8 g
(17% yield) of 11 as a dark foam. MALDI M/e 794.2 (Calc'd 796.4).
.sup.1H NMR (CDCl.sub.3, .delta.) 8.3 (d, 2H), 7.9(d, 2H), 7.75(d,
2H), 7.4-7.1(m, 9H), 6.7-6.5(m, 6H), 4.1(s, 3H), 3.95(s, 3H),
3.9-3.6(m, 12H), 3.3(t, 3H).
2.3 Synthesis of
4-nitrobenzylazo-2',5'-dimethoxybenzylazo-4''-N,N-(2-O-(N',N'-diisopropyl-
-2-cyanoethylphosphite)ethyl)-(2-O-(4,4'dimethoxy-trityl)ethyl)-azobenzene-
, (DMT-BH2 amidite), 12
[0248] A solution of 2.8 g (3.5 mmol) 11 in 50 mL of dry pyridine
was evaporated to dryness and high vacuum applied for several hrs.
A solution of 1.5 g (5 mmol) of
N,N,N',N'-tetraisopropyl-2-cyanoethylphosphane and 60 mg of
tetrazole were mixed in 20 mL of dry acetonitrile and added to the
flask containing the dried 11. After 2 hrs, the solvent was
stripped, and the residue was dissolved in 200 mL of EtOAc. The
organic layer was washed with 100 mL sat'd aqueous NaHCO.sub.3 and
dried over MgSO.sub.4. The solvent was evaporated, and the residue
applied to a 25 by 3 cm chromatography column of neutral alumina,
7% by weight water, and eluted with a mobile phase of 75% Pet.
ether, 23% EtOAc, 2% pyridine. Fractions containing pure 12 (0.71
rf, pre-run silica plate, 50% Pet. ether, 48% EtOAc, 2% pyridine)
were pooled and evaporated. The yield was 1 g (20% yield) of 11 as
a dark foam. MALDI M/e 996.06 (Calc'd 996.4).
2.4 Synthesis of BH2-CPG, 13
[0249] 10 g DMT-2,2'-sulfonyldiethanol-succinyl controlled pore
glass, 500 .ANG., Biosearch part # BG5-5000, was washed three times
with 3% dichloroacetic acid to effect removal of the DMT group. The
CPG was washed well with three 50 mL portions of CH.sub.2Cl.sub.2,
followed by one 50 mL wash with dry pyridine. The CPG was added to
the flask containing 1 g of 12. 25 mL of dry pyridine was added,
and the solvent was removed by rotary evaporation, followed by high
vacuum for 3 hrs. The dried CPG and amidite were treated with a
solution of 1 g S-ethyl tetrazole in 20 mL of dry acetonitrile for
20 min. The CPG was washed in a sintered glass funnel twice with 50
mL of acetonitrile, then 50 mL of 0.02 M iodine in 90% THF, 8%
water and 2% pyridine were added. After 5 min, the iodine solution
was washed out of the CPG with three 50 mL portions of
acetonitrile, then a capping solution of 10% Ac.sub.2O, 10%
N-methylimidazole and 10% pyridine in THF was added. After 20 min,
the solution was washed out of the CPG with three 50 mL portions of
acetonitrile, followed by three 50 mL portions of CH.sub.2Cl.sub.2.
The material was dried overnight under high vacuum. DMT loading
determination on the dried material was 30 .mu.M/g.
Example 3
[0250] This Example sets forth the synthesis and characterization
of BH3 and derivatives thereof.
3.1 Synthesis of
3-diethylamino-5-phenylphenazium-7-(4'-N,N-di(2-hydroxyethyl)azobenzene)c-
hloride, (BH3 diol), 14
[0251] 3-amino-7-(diethylamino)-5-phenylphenazium chloride
(methylene violet 3RAX, Aldrich 30,750-5), 10 g (26 mmol) was
stirred in 200 mL 1 N HCl while in an ice bath. A solution of 2 g
NaNO.sub.2 in 20 mL of cold water was added dropwise over 20 min.
The solution was stirred for 30 min. N-phenyldiethanolamine, 4.7 g
(27 mmol), was dissolved in 100 mL of methanol and added to the
methylene violet solution, after the pH was adjusted to 6 with NaOH
solution. The solution changed color from violet to dark green. The
solution was stirred for 1 hr, then extracted three times with 200
mL of CH.sub.2Cl.sub.2. The aqueous layer was evaporated, and the
dark green solid was triturated with 3 200 mL portions of pyridine.
The pyridine was evaporated to give 2.9 g (21% yield) of 14 as a
dark green solid. (0.85 rf, silica plate, 15% MeOH, 2% pyridine in
CH.sub.2Cl.sub.2) MALDI M/e 535.6 (calc'd 535.75).
3.2 Synthesis of
3-diethylamino-5-phenylphenazium-7-(4'-N,N-(2-hydroxyethyl)-(2-O-(4,4'dim-
ethoxytrityl)ethylazobenzene chloride, (DMT-BH3), 15
[0252] Compound 14, 2.9 g (5.4 mmol) was dried by stripping with
100 mL dry pyridine, and then re-dissolved in 100 mL dry pyridine
along with 2 g (5.9 mmol) of DMT chloride. The mixture sat
overnight, and the solvent was stripped. The residue was
re-dissolved in 200 mL CH.sub.2Cl.sub.2 and washed with 200 mL 1 M
aqueous citric acid. The aqueous layer was backwashed with two 200
mL portions of CH.sub.2Cl.sub.2, and the combined organic layers
were evaporated to a tar. The residue was loaded onto a 20 by 3 cm
chromatography column of neutral alumina, 7% by weight water, and
eluted first with a mobile phase of 2% MeOH, 1% pyridine in
CH.sub.2Cl.sub.2. A gradient to 6% MeOH was run over 3 L. Fractions
containing pure 15 (0.9 rf, silica plate, 15% MeOH, 1% pyridine in
CH.sub.2Cl.sub.2) were pooled and evaporated. The yield was 0.5 g
(11% yield) of 15 as a dark foam. MALDI M/e 837.6 (calc'd
836.75)
3.3 Synthesis of
3-diethylamino-5-phenylphenazium-7-(4'-N,N-(2-O-(N',N'-diisopropyl-2-cyan-
oethylphosphite)ethyl)-(2-O-(4,4'dimethoxy-trityl)ethyl)azobenzene
chloride, (DMT-BH3 amidite), 16
[0253] A solution of 0.5 g (0.6 mmol) 15 in 50 mL of dry pyridine
was evaporated to dryness and high vacuum applied for several hrs.
A solution of 0.5 g (1.7 mmol) of
N,N,N',N'-tetraisopropyl-2-cyanoethylphosphane and 20 mg of
tetrazole were mixed in 20 mL of dry acetonitrile and added to the
flask containing the dried 15. After 2 hrs, the solvent was
stripped, and the residue was dissolved in 100 mL of EtOAc. The
organic layer was washed with 50 mL sat'd aqueous NaHCO.sub.3 and
dried over MgSO.sub.4. The solvent was evaporated, and the residue
applied to a 15 by 3 cm chromatography column of neutral alumina,
7% by weight water, and eluted first with a mobile phase of 1%
MeOH, 1% pyridine in CH.sub.2Cl.sub.2. A gradient to 6% MeOH was
run over 2 L. Fractions containing pure 16 (0.82 rf, pre-run silica
plate, 5% MeOH, 1% pyridine in CH.sub.2Cl.sub.2) were pooled and
evaporated. The yield was 0.26 g (42% yield) of 16 as a dark foam.
MALDI M/e 1037.3 (Calc'd 1036.75).
Synthesis of BH3-CPG, 17
[0254] 2 g DMT-2,2'-sulfonyldiethanol-succinyl controlled pore
glass, 500 .ANG., Biosearch part # BG5-5000, was washed three times
with 3% dichloroacetic acid to effect removal of the DMT group. The
CPG was washed well with three 20 mL portions of CH.sub.2Cl.sub.2,
followed by one 20 mL wash with dry pyridine. The CPG was added to
the flask containing 0.26 g of 16. 25 mL of dry pyridine was added,
and the solvent was removed by rotary evaporation, followed by high
vacuum for 3 hrs. The dried CPG and amidite were treated with a
solution of 0.5 g S-ethyl tetrazole in 10 mL of dry acetonitrile
for 20 min. The CPG was washed in a sintered glass funnel twice
with 20 mL of acetonitrile, then 20 mL of 0.02 M iodine in 90% THF,
8% water and 2% pyridine were added. After 5 min, the iodine
solution was washed out of the CPG with three 20 mL portions of
acetonitrile, then a capping solution of 10% Ac.sub.2O, 10%
N-methylimidazole and 10% pyridine in THF was added. After 20 min,
the solution was washed out of the CPG with three 20 mL portions of
acetonitrile, followed by three 20 mL portions of CH.sub.2Cl.sub.2.
The material was dried overnight under high vacuum. DMT loading
determination on the dried material was 12 .mu.M/g.
Example 4
[0255] This Example sets forth the preparation and characterization
of nucleic acid analogues of exemplary BHQs of the invention. The
nucleic acid-BHQ conjugates are compared to a similar conjugate of
DABCYL.
[0256] The efficiency of donor-acceptor energy transfer (FRET) is
inversely proportional to the sixth power of the distance between
the donor and acceptor molecules (Stryer, L. Annu. Rev. Biochem.
1978, 47, 819-846). This property can be utilized to monitor
hybridization of nucleic acids labeled at one end with a donor
fluorophore (reporter) and at the opposite end with an acceptor
(quencher) (Parkhurst et al., Biochemistry 1995, 34, 285-292). In
the absence of a complementary target sequence the dual labeled
probe is very flexible and undergoes rapid conformational changes
so that the average distance between the donor (D) and acceptor (A)
is close enough for efficient FRET to occur. Upon hybridization to
complementary target, a rigid DNA duplex is formed separating the
D-A pair and reducing the efficiency of transfer. This manifests
itself in an increase in the fluorescence intensity of the
reporter.
4.1 Synthesis and Characterization of BHQ Probes
[0257] To evaluate the efficiency of the Black Hole Quencher dyes
(BHQs), the ability of these dyes to quench a series of common
fluorophores was compared to the standard quencher dyes DABCYL and
TAMRA in a complementation assay. As TAMRA exhibits its own native
fluorescence, it can only be used to quench lower wavelength dyes
and thus was only used to quench FAM in this assay.
4.1a Materials and Methods
[0258] Nucleic acids were synthesized on a Biosearch 8700 automated
DNA synthesizer using standard phosphoramidite chemistry. A.sup.BZ,
C.sup.AC, T, and G.sup.DMF phosphoramidites were supplied by
Chruachem. TAMRA, DABCYL, and BHQ controlled pore glass (CPG)
supports from Biosearch Technologies were used for attachment of
quencher dyes to the 3' terminus of nucleic acids. 5' fluorophore
labeling was accomplished using fluorophore phosphoramidites with
the exception of Cy5 which was added as a succinimidyl ester to 5'
amino nucleic acids using the manufacturers' protocol. 6-FAM and
TFA-aminohexyl amidite were from Biosearch. Cy3 phosphoramidite and
Cy5 succinimidyl ester were from Amersham Pharmacia Biotech.
Cleavage and deprotection of oligos was carried out in ammonia at
60.degree. C. for 3 hrs, with the exception of 3' TAMRA oligos
which were deprotected in 1:3 t-butylamine:H.sub.2O for 8 hours at
60.degree. C., and 3' BH3 oligos which were deprotected for 1 hour
at 60.degree. C. in ammonia. Following deprotection, dual labeled
probes were evaporated to dryness then resuspended in HPLC grade
water and filtered through 0.45 .mu.M filters to prepare for HPLC
purification. A two step method of HPLC purification of anion
exchange followed by reverse phase HPLC was used to purify all dual
labeled probes. Purified probes were analyzed by both anion
exchange and reverse phase HPLC. Complementary nucleic acid was
purified on a Biosearch Micropure II reverse phase cartridge using
the standard protocol.
[0259] All fluorescence measurements were taken using a Spectramax
Gemini fluorescent microplate reader. Probes were dissolved at 200
nM in a buffer composed of of 10 mM Tris-HCl, 50 mM KCl, and 3.5 mM
MgCl.sub.2, pH 8.3, both in the presence and absence of a five fold
excess of perfectly complimentary nucleic acid. Fluorescein was
excited at 470 nm and emission was read at 530 nm with a 515 nm
cutoff filter in place. Cy3 was excited at 510 nm and read at 567
nm with a 550 nm cutoff filter. Cy5 was excited at 630 nm and read
at 660 nm with a 630 nm cutoff filter. Average fluorescent
intensity from a set of eight buffer blanks was subtracted from all
probe fluorescence measurements before calculation of signal to
noise ratios.
[0260] The set of nucleic acids displayed in Table 2 was
synthesized and rigorously purified by HPLC: TABLE-US-00002 TABLE 2
Dual labeled probes prepared for hybridization assay. Reporter em
max Quencher (5') (nm) Sequence (5' to 3') (3') FAM 518 ATG CCC TCC
CCC ATG CCA TCC TAMRA TGC G FAM 518 ATG CCC TCC CCC ATG CCA TCC
DABCYL TGC G FAM 518 ATG CCC TCC CCC ATG CCA TCC BH1 TGC G FAM 518
ATG CCC TCC CCC ATG CCA TCC BH2 TGC G Cy3 573 ATG CCC TCC CCC ATG
CCA TCC DABCYL TGC G Cy3 573 ATG CCC TCC CCC ATG CCA TCC BH1 TGC G
Cy3 573 ATG CCC TCC CCC ATG CCA TCC BH2 TGC G Cy5 678 ATG CCC TCC
CCC ATG CCA TCC DABCYL TGC G Cy5 678 ATG CCC TCC CCC ATG CCA TCC
BH2 TGC G Cy5 678 ATG CCC TCC CCC ATG CCA TCC BH3 TGC G
[0261] The signal to noise ratio (S:N) of hybridization for each
probe was measured in the presence of a five fold molar excess of
perfectly complementary nucleic acid. All hybridization assays were
performed in a buffer composed of 10 mM Tris-HCl, 50 mM KCl, and
3.5 mM MgCl.sub.2, pH 8.3. S:N was calculated by dividing the
fluorescence intensity of the probe in the presence of complement
by the fluorescence intensity of the probe alone after subtracting
out the fluorescence intensity of the buffer blank from each. All
fluorescence measurements were taken in triplicate using a
Spectramax Gemini fluorescent plate reader.
4.2 Results
[0262] Improved quenching by the BHQs was demonstrated for three
widely separated fluorophores. A two fold increase in signal to
noise ratio is achieved by replacing DABCYL with BH1 for the
fluorescein probe. S:N increases are more striking for the cyanine
dye labeled probes, with approximately a ten fold increase in S:N
observed for the BH2 quenched Cy3 probe and a thirty fold S:N
increase for the BH3 quenched Cy5 probe over identical structures
quenched with DABCYL. This is consistant with the theory that
efficiency of FRET is proportional to the magnitude of overlap
between the donor and acceptor (Haugland et al., Proc. Natl. Acad.
Sci. U.S.A. 1969, 63, 23-30). DABCYL, which absorbs maximally at
474 nm, quenches the red shifted reporter dyes with decreasing
efficiency, whereas the BHQs can be chosen accordingly to have
maximum spectral overlap with the reporter of interest.
[0263] Data from the hybridization assay is presented in Table 3.
TABLE-US-00003 TABLE 3 Signal to noise ratios of dual labeled FRET
probes donor/acceptor Noise Signal Average Average measurement no.
#1 #2 #3 #1 #2 #3 Noise Signal S:N FAMTAM 89.18 91.50 89.54 279.13
277.08 272.78 90.08 276.33 3.07 FAMDAB 89.97 81.03 86.74 348.98
323.82 352.00 85.92 341.61 3.98 FAMBH1 39.24 37.05 38.85 296.53
316.24 311.15 38.38 307.97 8.02 FAMBH2 67.12 66.64 56.79 445.48
415.78 442.75 63.52 434.34 6.84 Cy3DAB 19.66 19.65 19.39 147.70
139.83 154.35 19.57 147.29 7.53 Cy3BH1 1.86 2.09 2.41 140.72 135.20
135.25 2.12 137.06 64.51 Cy3BH2 2.02 1.94 2.08 149.65 148.89 150.40
2.02 149.65 74.15 Cy5/DAB 57.09 59.15 50.50 157.36 176.04 216.59
55.58 183.33 3.30 Cy5/BH2 19.92 21.47 22.53 263.64 288.20 256.07
21.31 269.31 12.64 Cy5/BH3 1.65 2.17 1.55 197.96 210.71 208.06 1.79
205.58 114.79
[0264] It is understood that the examples and embodiments described
herein are for illustrative purposes only and that various
modifications or changes in light thereof will be suggested to
persons skilled in the art and are to included within the spirit
and purview of this application and are considered within the scope
of the appended claims. All publications, patents, and patent
applications cited herein are hereby incorporated by reference in
their entirety for all purposes.
Sequence CWU 1
1
1 1 25 DNA Artificial probe synthetic 1 atgccctccc ccatgccatc ctgcg
25
* * * * *